cilostazol has been researched along with Disease Models, Animal in 132 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To clarify the potential protective role of cilostazol on rat myocardial cells with ischemia-reperfusion injury (IRI) models." | 8.12 | Cardioprotective Effect of Cilostazol on Ischemia-Reperfusion Injury Model. ( Baytaroglu, C; Sahin, M; Sevgili, E, 2022) |
| "The cilostazol regimen, attenuated prenatal VPA exposure associated hyperlocomotion, social interaction deficits, repetitive behavior, and anxiety." | 8.02 | Cilostazol attenuated prenatal valproic acid-induced behavioural and biochemical deficits in a rat model of autism spectrum disorder. ( Kulkarni, GT; Luhach, K; Sharma, B; Singh, VP, 2021) |
| "The phosphodiesterase-3 inhibitor, cilostazol has been recently shown to protect against chemically induced colitis in animal models." | 7.96 | Cilostazol protects against acetic acid-induced colitis in rats: Possible role for cAMP/SIRT1 pathway. ( Elhassanny, AEM; Elshazly, SM; Mahmoud, NM, 2020) |
| "The influence of cilostazol on learning and memory, and cyclin D1 expression in the cerebral cortex of rats with chronic cerebral ischemia were investigated." | 7.96 | Influence of Cilostazol on Changes in Cyclin D1 Expression in Cerebral Cortex of Rats with Chronic Cerebral Ischemia. ( Liu, Y; Ma, XY; Mang, J; Shao, MY; Sun, Y; Wang, LM; Wei, AX; Xu, ZX, 2020) |
| "Postoperative enteral administration of cilostazol increased blood flow and decreased the total area of necrosis of avulsed cutaneous flaps of rat limbs." | 7.88 | Effect of cilostazol in experimental model of degloving injuries in rat limbs. ( Pazio, A; Salles Junior, GS; Santos, VB, 2018) |
| "The aim of this study was to determine the effects and underlying mechanism of aripiprazole (APZ) augmentation for cilostazol (CLS)-treated post-ischemic stroke mice that were exposed to chronic mild stress (CMS)." | 7.85 | Antidepressant Effects of Aripiprazole Augmentation for Cilostazol-Treated Mice Exposed to Chronic Mild Stress after Ischemic Stroke. ( Choi, BT; Hong, KW; Kim, HN; Kim, YR; Shin, HK, 2017) |
| "Our results suggest that phosphodiesterase 3 inhibitor cilostazol may have anti-depressant effects on post-stroke depression through inhibition of neurodegeneration in the primary lesion and secondary extrafocal sites and promotion of neurogenesis." | 7.83 | Anti-depressant effects of phosphodiesterase 3 inhibitor cilostazol in chronic mild stress-treated mice after ischemic stroke. ( Choi, BT; Hong, KW; Kim, HN; Kim, YR; Shin, HK, 2016) |
| "The aim of this study was to evaluate the pretreatment effect of cilostazol on spinal cord ischemia-reperfusion injury." | 7.81 | Cilostazol attenuates spinal cord ischemia-reperfusion injury in rabbits. ( Alpay, MF; Cakir, O; Colak, N; Erdamar, H; Haltas, H; Namuslu, M; Nazli, Y; Nuri Aksoy, O; Olgun Akkaya, I, 2015) |
| "Cilostazol and L-carnitine have been used as a first-line drug and supplement, respectively, in patients with peripheral arterial disease with intermittent claudication." | 7.81 | Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats. ( Orito, K; Sahara, H; Shiga, T, 2015) |
| "These results indicate that cilostazol is neuroprotective in the chronically compressed cervical cord and is potentially useful in the treatment of cervical spondylotic myelopathy." | 7.80 | Cilostazol, a selective Type III phosphodiesterase inhibitor: prevention of cervical myelopathy in a rat chronic compression model. ( Kim, P; Kurokawa, R; Yamamoto, S, 2014) |
| "We studied ischemia-induced neovascularization in the ischemic hindlimb of cilostazol-treated and untreated control mice." | 7.79 | Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. ( Angelini, F; Arena, V; Biscetti, F; Flex, A; Ghirlanda, G; Locatelli, F; Pecorini, G; Rutella, S; Stigliano, E; Straface, G, 2013) |
| "Our study identifies milrinone as a more potent alternative to cilostazol for reversing the repolarization defects responsible for the electrocardiographic and arrhythmic manifestations of Brugada syndrome." | 7.79 | Cellular mechanisms underlying the effects of milrinone and cilostazol to suppress arrhythmogenesis associated with Brugada syndrome. ( Antzelevitch, C; Koncz, I; Szél, T, 2013) |
| "The present study assessed the effects of cilostazol on LPS-stimulated TLR4 signal pathways in synovial macrophages from patients with rheumatoid arthritis (RA)." | 7.79 | Suppression of PU.1-linked TLR4 expression by cilostazol with decrease of cytokine production in macrophages from patients with rheumatoid arthritis. ( Baek, SH; Hong, KW; Kim, CD; Lee, CW; Lee, SW; Lee, WS; Park, SY; Rhim, BY, 2013) |
| "To investigate the effect of cilostazol, in kidney and skeletal muscle of rats submitted to acute ischemia and reperfusion." | 7.78 | Effects of cilostazol in kidney and skeletal striated muscle of Wistar rats submitted to acute ischemia and reperfusion of hind limbs. ( Capelozzi, VL; Francisco Neto, A; Moreira Neto, AA; Parra-Cuentas, ER; Rodrigues, OR; Schmidt Júnior, AF; Souza Júnior, SS, 2012) |
| "This study aimed to assess the beneficial effects of the concurrent administration of cilostazol and methotrexate (MTX) on the synovial fibroblasts obtained from patients with rheumatoid arthritis (RA), and in a mouse model of collagen-induced arthritis (CIA)." | 7.78 | Efficacy of concurrent administration of cilostazol and methotrexate in rheumatoid arthritis: pharmacologic and clinical significance. ( Baek, SH; Hong, KW; Kim, CD; Kim, HY; Lee, CW; Lee, SW; Park, SY, 2012) |
| "Acetylcholine-and A23187-induced relaxation was reduced in the Ischemia/Reperfusion 120/90 group, and treatment with cilostazol partially prevented this ischemia/reperfusion-induced endothelium impairment." | 7.78 | The protective effect of cilostazol on isolated rabbit femoral arteries under conditions of ischemia and reperfusion: the role of the nitric oxide pathway. ( Capellini, VK; Celotto, AC; Evora, PR; Joviliano, EE; Piccinato, CE; Santos, MR, 2012) |
| "These results demonstrate that the protective effect of cilostazol against neointimal hyperplasia may be mediated by its anti-inflammatory actions of mononuclear cells homing to endothelial cells by decreasing SLX and E-selectin expression." | 7.78 | Cilostazol suppression of arterial intimal hyperplasia is associated with decreased expression of sialyl Lewis X homing receptors on mononuclear cells and E-selectin in endothelial cells. ( Matsumura, A; Nakamura, K; Suzuki, K; Takigawa, T; Tsurushima, H; Tsuruta, W, 2012) |
| "In the non-rtPA cohort, pretreatment by cilostazol significantly decreased the endothelial expression of adhesion molecules (P-selectin and intercellular adhesion molecule-1) and prevented platelet aggregation and leukocyte plugging in the microvessels after cerebral ischemia/reperfusion in the acute phase." | 7.78 | Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia. ( Fujita, Y; Hase, Y; Ihara, M; Ito, H; Kitamura, A; Maki, T; Nakabayashi, H; Okamoto, Y; Takahashi, R; Washida, K, 2012) |
| " The present study examined whether or not cilostazol reduces the myocardial infarct size, and investigated its mechanism in a rabbit model of myocardial infarction." | 7.77 | Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels. ( Aoyama, T; Bai, Y; Iwasa, M; Minatoguchi, S; Murakami, H; Nishigaki, K; Sumi, S; Takemura, G; Uno, B; Ushikoshi, H; Yamada, Y, 2011) |
| "To investigate the protective effect of cilostazol administrated intranasally on chronic injury after focal cerebral ischemia in mice." | 7.77 | [Protective effect of intranasal cilostazol administration on chronic injury after cerebral ischemia in mice]. ( Jiang, LL; Li, Q; Wei, EQ; Ye, YL; Yu, YP; Zhang, Q; Zhang, WP, 2011) |
| "Selective inhibition of phosphodiesterase type III (PDE III) may be involved in the pathophysiology of vasospasm and a PDE III inhibitor, cilostazol, is thus expected to attenuate vasospasm after subarachnoid hemorrhage (SAH)." | 7.75 | Multifaceted effects of selective inhibitor of phosphodiesterase III, cilostazol, for cerebral vasospasm after subarachnoid hemorrhage in a dog model. ( Mizutani, A; Namba, H; Nishizawa, S; Yamaguchi-Okada, M, 2009) |
| "Two PDE inhibitors including cilostazol a PDE3 inhibitor (40 and 400 mg/kg), and pentoxifylline (PTX), a PDE 1-5 inhibitor (50 and 500 mg/kg) were used for a period of 7 days to inhibit angiogenesis, inflammation, and fibrosis in a murine model of sponge-induced peritoneal adhesion." | 7.75 | Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice. ( Andrade, SP; Campos, PP; Mendes, JB; Rocha, MA, 2009) |
| "Our aim in this study was to investigate the efficacy of intravenous administration of cilostazol and compare these effects with intravenous usage of nimodipine in subarachnoid hemorrhage model." | 7.75 | The effects of intravenous cilostazol and nimodipine on cerebral vasospasm after subarachnoid hemorrhage in an experimental rabbit model. ( Bilginer, B; Narin, F; Onal, MB; Ozgen, T; Soylemezoglu, F; Ziyal, IM, 2009) |
| "To evaluate whether delayed treatment with the antiplatelet agent cilostazol reduces the volume of infarction in the gray and white matter in a rodent model of permanent focal cerebral ischemia and to explore the mechanism of the neuroprotective effect in vivo." | 7.73 | Cilostazol attenuates gray and white matter damage in a rodent model of focal cerebral ischemia. ( Fukunaga, M; Honda, F; Imai, H; Ishikawa, M; Kubota, C; Saito, N; Shimizu, T, 2006) |
| "The systemic treatment effects of OP-1206 alpha-CD (17S-20-dimethyl-trans-delta 2-PGE1 alpha-cyclodextrin clathrate), a prostaglandin E1 (PGE1) analogue, on walking dysfunction, spinal cord blood flow (SCBF) and skin blood flow (SKBF) were assessed in the rat neuropathic intermittent claudication (IC) model in comparison with nifedipine (dimethyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate), ticlopidine (5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-C]pyridine hydrochloride) and cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone)." | 7.72 | Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol. ( Akimaru, S; Ito, H; Katsube, N; Maegawa, H; Marsala, M; Nakai, K; Takenobu, Y; Takimizu, H, 2003) |
| "These findings suggested that cilostazol may improve insulin resistance in STZ-induced non-insulin dependent diabetic rats." | 7.71 | The effect of cilostazol on glucose tolerance and insulin resistance in a rat model of non-insulin dependent diabetes mellitus. ( Ahn, YB; Cha, BY; Chang, SA; Han, JH; Kang, MI; Kang, SK; Lee, JM; Lee, KW; Son, HS; Son, HY; Song, KH; Yoo, SJ; Yoon, KH, 2001) |
| "Cilostazol (CSZ) has been shown to be a new treatment for cognitive impairment with limited efficacy." | 5.72 | Advancing combination treatment with cilostazol and caffeine for Alzheimer's disease in high fat-high fructose-STZ induced model of amnesia. ( Ahmed, AM; El-Mokhtar, MA; Farghaly, HSM; Gomaa, AA; Hemida, FK, 2022) |
| "Cilostazol is a drug of choice for the treatment of intermittent claudication that also affects innate and adaptive immune cells." | 5.56 | Cilostazol Mediates Immune Responses and Affects Angiogenesis During the Acute Phase of Hind Limb Ischemia in a Mouse Model. ( Bouziotis, P; Kadoglou, NPE; Kakisis, I; Katsimpoulas, M; Kostomitsopoulos, NG; Kostopoulos, IV; Lazaris, A; Paronis, E; Poulaki, E; Prignon, A; Provost, C; Spyropoulos, C; Stasinopoulou, M; Tsitsilonis, O, 2020) |
| "Stroke is the major cause of death and decrease in the activities of daily living." | 5.40 | Neurovascular protection of cilostazol in stroke-prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation. ( Abe, K; Deguchi, K; Ikeda, Y; Kono, S; Kurata, T; Liu, N; Liu, W; Omote, Y; Yamashita, T, 2014) |
| "Hypothermia has been reported to induce ventricular tachycardia and fibrillation (VT/VF) in patients with early repolarization (ER) pattern." | 5.40 | Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone. ( Antzelevitch, C; Gurabi, Z; Koncz, I; Nesterenko, VV; Patocskai, B, 2014) |
| "Nimodipine is a calcium channel blocker and is still used in vasospasm therapy either oral or intravenously." | 5.37 | Comparison of intrathecal cilostazol and nimodipine treatments in subarachnoid hemorrhage: an experimental study in rabbits. ( Bilginer, B; Narin, F; Onal, MB; Ozgen, T; Soylemezoglu, F; Ziyal, MI, 2011) |
| "We investigated these effects on cerebral vasospasm after rat SAH." | 5.36 | Cilostazol attenuates cerebral vasospasm after experimental subarachnoid hemorrhage. ( Fujinaka, T; Nishino, A; Umegaki, M; Yoshimine, T, 2010) |
| "Pretreatment with cilostazol significantly attenuated the increased migration of monocytes, possibly through suppression of platelet-monocyte interactions." | 5.35 | Cilostazol, a specific PDE-3 inhibitor, ameliorates chronic ileitis via suppression of interaction of platelets with monocytes. ( Higashiyama, M; Hokari, R; Kawaguchi, A; Komoto, S; Kurihara, C; Matsunaga, H; Miura, S; Nagao, S; Nakamura, M; Okada, Y; Watanabe, C, 2009) |
| "In the present study, cerebral ischemia was induced by a 10 min transient bilateral common carotid artery occlusion in rats combined with arterial blood pressure lowering to 37-42 mm Hg during occlusion." | 5.35 | Cilostazol preserves CA1 hippocampus and enhances generation of immature neuroblasts in dentate gyrus after transient forebrain ischemia in rats. ( Hong, KW; Kim, CD; Lee, JH; Lee, WS; Park, SY; Shin, HK, 2009) |
| "To clarify the potential protective role of cilostazol on rat myocardial cells with ischemia-reperfusion injury (IRI) models." | 4.12 | Cardioprotective Effect of Cilostazol on Ischemia-Reperfusion Injury Model. ( Baytaroglu, C; Sahin, M; Sevgili, E, 2022) |
| "The cilostazol regimen, attenuated prenatal VPA exposure associated hyperlocomotion, social interaction deficits, repetitive behavior, and anxiety." | 4.02 | Cilostazol attenuated prenatal valproic acid-induced behavioural and biochemical deficits in a rat model of autism spectrum disorder. ( Kulkarni, GT; Luhach, K; Sharma, B; Singh, VP, 2021) |
| "The phosphodiesterase-3 inhibitor, cilostazol has been recently shown to protect against chemically induced colitis in animal models." | 3.96 | Cilostazol protects against acetic acid-induced colitis in rats: Possible role for cAMP/SIRT1 pathway. ( Elhassanny, AEM; Elshazly, SM; Mahmoud, NM, 2020) |
| "The influence of cilostazol on learning and memory, and cyclin D1 expression in the cerebral cortex of rats with chronic cerebral ischemia were investigated." | 3.96 | Influence of Cilostazol on Changes in Cyclin D1 Expression in Cerebral Cortex of Rats with Chronic Cerebral Ischemia. ( Liu, Y; Ma, XY; Mang, J; Shao, MY; Sun, Y; Wang, LM; Wei, AX; Xu, ZX, 2020) |
| "Mice were orally administered cilostazol plus pravastatin (CILOP) or cilostazol plus rosuvastatin (CILOR), clopidogrel plus pravastatin (CLOP), or clopidogrel plus rosuvastatin (CLOR); then, acute inflammation was induced by the injection of lipopolysaccharide (LPS) or TNF." | 3.91 | A Comparison of the Anti-Inflammatory Effects of Four Combined Statin and Antiplatelet Therapies on Tumor Necrosis Factor-Mediated Acute Inflammation in vivo. ( Cho, O; Heo, TH; Kim, HS; Park, KY, 2019) |
| "Mice were administered rosuvastatin alone, cilostazol alone or rosuvastatin and cilostazol in combination, and then injected with LPS or TNF to induce acute inflammation." | 3.91 | Beneficial anti-inflammatory effects of combined rosuvastatin and cilostazol in a TNF-driven inflammatory model. ( Cho, O; Heo, TH; Jang, YJ; Park, KY, 2019) |
| "Postoperative enteral administration of cilostazol increased blood flow and decreased the total area of necrosis of avulsed cutaneous flaps of rat limbs." | 3.88 | Effect of cilostazol in experimental model of degloving injuries in rat limbs. ( Pazio, A; Salles Junior, GS; Santos, VB, 2018) |
| "Aspirin prevented aneurysm rupture in a mouse intracranial aneurysm model, while cilostazol did not." | 3.88 | Prevention Effect of Antiplatelets on Aneurysm Rupture in a Mouse Intracranial Aneurysm Model. ( Hiramatsu, H; Hokamura, K; Kamio, Y; Kimura, T; Makino, H; Namba, H; Suzuki, T; Umemura, K; Yamasaki, T, 2018) |
| " We examined the inhibitory effects of a selective phosphodiesterase-3 inhibitor, cilostazol (CZ), and two antioxidants, enzymatically modified isoquercitrin (EMIQ) and α-lipoic acid (ALA), against dextran sulphate sodium (DSS)-induced colitis." | 3.85 | Anti-inflammatory effects of the selective phosphodiesterase 3 inhibitor, cilostazol, and antioxidants, enzymatically-modified isoquercitrin and α-lipoic acid, reduce dextran sulphate sodium-induced colorectal mucosal injury in mice. ( Abe, H; Hayashi, SM; Kangawa, Y; Kihara, T; Miyashita, T; Nakamura, M; Seto, Y; Shibutani, M; Yoshida, T, 2017) |
| "The aim of this study was to determine the effects and underlying mechanism of aripiprazole (APZ) augmentation for cilostazol (CLS)-treated post-ischemic stroke mice that were exposed to chronic mild stress (CMS)." | 3.85 | Antidepressant Effects of Aripiprazole Augmentation for Cilostazol-Treated Mice Exposed to Chronic Mild Stress after Ischemic Stroke. ( Choi, BT; Hong, KW; Kim, HN; Kim, YR; Shin, HK, 2017) |
| "Our results suggest that phosphodiesterase 3 inhibitor cilostazol may have anti-depressant effects on post-stroke depression through inhibition of neurodegeneration in the primary lesion and secondary extrafocal sites and promotion of neurogenesis." | 3.83 | Anti-depressant effects of phosphodiesterase 3 inhibitor cilostazol in chronic mild stress-treated mice after ischemic stroke. ( Choi, BT; Hong, KW; Kim, HN; Kim, YR; Shin, HK, 2016) |
| " We performed cognitive behavioral tests, including the water maze task, odor discrimination task, and novel object test; histological investigation of neuroinflammation, oligodendrocytes, myelin basic protein, and nodal or paranodal proteins at the nodes of Ranvier; and serial diffusion tensor imaging." | 3.83 | Characterization of White Matter Injury in a Rat Model of Chronic Cerebral Hypoperfusion. ( Back, DB; Choi, BR; Choi, DH; Han, JS; Han, SH; Kang, CH; Kim, BR; Kim, DH; Kim, HY; Kwon, KJ; Lee, J; Moon, WJ; Shin, CY, 2016) |
| "The aim of this study was to evaluate the pretreatment effect of cilostazol on spinal cord ischemia-reperfusion injury." | 3.81 | Cilostazol attenuates spinal cord ischemia-reperfusion injury in rabbits. ( Alpay, MF; Cakir, O; Colak, N; Erdamar, H; Haltas, H; Namuslu, M; Nazli, Y; Nuri Aksoy, O; Olgun Akkaya, I, 2015) |
| "Cilostazol and L-carnitine have been used as a first-line drug and supplement, respectively, in patients with peripheral arterial disease with intermittent claudication." | 3.81 | Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats. ( Orito, K; Sahara, H; Shiga, T, 2015) |
| "These results indicate that cilostazol is neuroprotective in the chronically compressed cervical cord and is potentially useful in the treatment of cervical spondylotic myelopathy." | 3.80 | Cilostazol, a selective Type III phosphodiesterase inhibitor: prevention of cervical myelopathy in a rat chronic compression model. ( Kim, P; Kurokawa, R; Yamamoto, S, 2014) |
| "In this study, we investigated whether cilostazol has the potential to proliferate lymphatic vessels and to improve lymphatic function using human lymphatic endothelial cells (LECs) and mouse lymphedema models." | 3.80 | Cilostazol improves lymphatic function by inducing proliferation and stabilization of lymphatic endothelial cells. ( Chan, T; Fukuda, S; Hamazaki, TS; Kimura, T; Okochi, H; Sato, S; Sugaya, M; Tamura-Nakano, M, 2014) |
| "We analyzed the time to death in Mycobacterium tuberculosis-infected mice receiving type 4 PDE-Is (rolipram and cilomilast) and the impact on bacterial burden, time to clearance, and relapse when types 3 and 5 PDE-Is (cilostazol and sildenafil, respectively) and rolipram were added to the standard treatment." | 3.79 | Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. ( Ammerman, NC; Bishai, WR; Maiga, M; Maiga, MC; Murphy, R; Polis, M; Siddiqui, S; Tounkara, A, 2013) |
| " Long-term administration of cilostazol is more effective in reducing neointimal formation at non-overlapping segments of BESs in a porcine coronary model." | 3.79 | The impact of triple anti-platelet therapy for endothelialization and inflammatory response at overlapping bioabsorbable polymer coated drug-eluting stents in a porcine coronary model. ( Ahn, Y; Cho, JG; Hong, YJ; Jeong, MH; Kang, JC; Kim, JH; Kim, JM; Kim, KH; Lee, KH; Lim, KS; Park, DS; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS, 2013) |
| "The present study assessed the effects of cilostazol on LPS-stimulated TLR4 signal pathways in synovial macrophages from patients with rheumatoid arthritis (RA)." | 3.79 | Suppression of PU.1-linked TLR4 expression by cilostazol with decrease of cytokine production in macrophages from patients with rheumatoid arthritis. ( Baek, SH; Hong, KW; Kim, CD; Lee, CW; Lee, SW; Lee, WS; Park, SY; Rhim, BY, 2013) |
| "We studied ischemia-induced neovascularization in the ischemic hindlimb of cilostazol-treated and untreated control mice." | 3.79 | Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. ( Angelini, F; Arena, V; Biscetti, F; Flex, A; Ghirlanda, G; Locatelli, F; Pecorini, G; Rutella, S; Stigliano, E; Straface, G, 2013) |
| "Our study identifies milrinone as a more potent alternative to cilostazol for reversing the repolarization defects responsible for the electrocardiographic and arrhythmic manifestations of Brugada syndrome." | 3.79 | Cellular mechanisms underlying the effects of milrinone and cilostazol to suppress arrhythmogenesis associated with Brugada syndrome. ( Antzelevitch, C; Koncz, I; Szél, T, 2013) |
| "These results demonstrate that the protective effect of cilostazol against neointimal hyperplasia may be mediated by its anti-inflammatory actions of mononuclear cells homing to endothelial cells by decreasing SLX and E-selectin expression." | 3.78 | Cilostazol suppression of arterial intimal hyperplasia is associated with decreased expression of sialyl Lewis X homing receptors on mononuclear cells and E-selectin in endothelial cells. ( Matsumura, A; Nakamura, K; Suzuki, K; Takigawa, T; Tsurushima, H; Tsuruta, W, 2012) |
| "In the non-rtPA cohort, pretreatment by cilostazol significantly decreased the endothelial expression of adhesion molecules (P-selectin and intercellular adhesion molecule-1) and prevented platelet aggregation and leukocyte plugging in the microvessels after cerebral ischemia/reperfusion in the acute phase." | 3.78 | Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia. ( Fujita, Y; Hase, Y; Ihara, M; Ito, H; Kitamura, A; Maki, T; Nakabayashi, H; Okamoto, Y; Takahashi, R; Washida, K, 2012) |
| "Acetylcholine-and A23187-induced relaxation was reduced in the Ischemia/Reperfusion 120/90 group, and treatment with cilostazol partially prevented this ischemia/reperfusion-induced endothelium impairment." | 3.78 | The protective effect of cilostazol on isolated rabbit femoral arteries under conditions of ischemia and reperfusion: the role of the nitric oxide pathway. ( Capellini, VK; Celotto, AC; Evora, PR; Joviliano, EE; Piccinato, CE; Santos, MR, 2012) |
| "This study aimed to assess the beneficial effects of the concurrent administration of cilostazol and methotrexate (MTX) on the synovial fibroblasts obtained from patients with rheumatoid arthritis (RA), and in a mouse model of collagen-induced arthritis (CIA)." | 3.78 | Efficacy of concurrent administration of cilostazol and methotrexate in rheumatoid arthritis: pharmacologic and clinical significance. ( Baek, SH; Hong, KW; Kim, CD; Kim, HY; Lee, CW; Lee, SW; Park, SY, 2012) |
| "To investigate the effect of cilostazol, in kidney and skeletal muscle of rats submitted to acute ischemia and reperfusion." | 3.78 | Effects of cilostazol in kidney and skeletal striated muscle of Wistar rats submitted to acute ischemia and reperfusion of hind limbs. ( Capelozzi, VL; Francisco Neto, A; Moreira Neto, AA; Parra-Cuentas, ER; Rodrigues, OR; Schmidt Júnior, AF; Souza Júnior, SS, 2012) |
| "To investigate the protective effect of cilostazol administrated intranasally on chronic injury after focal cerebral ischemia in mice." | 3.77 | [Protective effect of intranasal cilostazol administration on chronic injury after cerebral ischemia in mice]. ( Jiang, LL; Li, Q; Wei, EQ; Ye, YL; Yu, YP; Zhang, Q; Zhang, WP, 2011) |
| " The present study examined whether or not cilostazol reduces the myocardial infarct size, and investigated its mechanism in a rabbit model of myocardial infarction." | 3.77 | Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels. ( Aoyama, T; Bai, Y; Iwasa, M; Minatoguchi, S; Murakami, H; Nishigaki, K; Sumi, S; Takemura, G; Uno, B; Ushikoshi, H; Yamada, Y, 2011) |
| "Cilostazol (CILO), a selective inhibitor of phosphodiesterase 3 with potent antithrombotic property, has been shown to have a vasculoprotective effect in atherosclerosis animal models due to its potential anti-inflammatory and antioxidant actions." | 3.76 | Vasculoprotective effect of cilostazol in aldosterone-induced hypertensive rats. ( Hirata, Y; Hirono, Y; Sakurada, M; Sekizawa, N; Suzuki, N; Yoshimoto, T, 2010) |
| "The purpose of this study was to investigate the efficacy of cilostazol for prevention of thrombosis in microsurgical anastomosis." | 3.76 | Cilostazol effectively reduces the decrease of flow volume in a thrombotic anastomosis model in a rat: a novel application of ultrasonography for evaluation. ( Chang, HW; Choi, TH; Han, K; Kim, JH; Kim, SH; Lee, SY; Park, J; Park, SH; Son, D; Suh, EH, 2010) |
| "Two PDE inhibitors including cilostazol a PDE3 inhibitor (40 and 400 mg/kg), and pentoxifylline (PTX), a PDE 1-5 inhibitor (50 and 500 mg/kg) were used for a period of 7 days to inhibit angiogenesis, inflammation, and fibrosis in a murine model of sponge-induced peritoneal adhesion." | 3.75 | Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice. ( Andrade, SP; Campos, PP; Mendes, JB; Rocha, MA, 2009) |
| "Selective inhibition of phosphodiesterase type III (PDE III) may be involved in the pathophysiology of vasospasm and a PDE III inhibitor, cilostazol, is thus expected to attenuate vasospasm after subarachnoid hemorrhage (SAH)." | 3.75 | Multifaceted effects of selective inhibitor of phosphodiesterase III, cilostazol, for cerebral vasospasm after subarachnoid hemorrhage in a dog model. ( Mizutani, A; Namba, H; Nishizawa, S; Yamaguchi-Okada, M, 2009) |
| "Our aim in this study was to investigate the efficacy of intravenous administration of cilostazol and compare these effects with intravenous usage of nimodipine in subarachnoid hemorrhage model." | 3.75 | The effects of intravenous cilostazol and nimodipine on cerebral vasospasm after subarachnoid hemorrhage in an experimental rabbit model. ( Bilginer, B; Narin, F; Onal, MB; Ozgen, T; Soylemezoglu, F; Ziyal, IM, 2009) |
| "To evaluate whether delayed treatment with the antiplatelet agent cilostazol reduces the volume of infarction in the gray and white matter in a rodent model of permanent focal cerebral ischemia and to explore the mechanism of the neuroprotective effect in vivo." | 3.73 | Cilostazol attenuates gray and white matter damage in a rodent model of focal cerebral ischemia. ( Fukunaga, M; Honda, F; Imai, H; Ishikawa, M; Kubota, C; Saito, N; Shimizu, T, 2006) |
| "The systemic treatment effects of OP-1206 alpha-CD (17S-20-dimethyl-trans-delta 2-PGE1 alpha-cyclodextrin clathrate), a prostaglandin E1 (PGE1) analogue, on walking dysfunction, spinal cord blood flow (SCBF) and skin blood flow (SKBF) were assessed in the rat neuropathic intermittent claudication (IC) model in comparison with nifedipine (dimethyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate), ticlopidine (5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-C]pyridine hydrochloride) and cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone)." | 3.72 | Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol. ( Akimaru, S; Ito, H; Katsube, N; Maegawa, H; Marsala, M; Nakai, K; Takenobu, Y; Takimizu, H, 2003) |
| "These findings suggested that cilostazol may improve insulin resistance in STZ-induced non-insulin dependent diabetic rats." | 3.71 | The effect of cilostazol on glucose tolerance and insulin resistance in a rat model of non-insulin dependent diabetes mellitus. ( Ahn, YB; Cha, BY; Chang, SA; Han, JH; Kang, MI; Kang, SK; Lee, JM; Lee, KW; Son, HS; Son, HY; Song, KH; Yoo, SJ; Yoon, KH, 2001) |
| " Pharmacokinetics and pharmacodynamic (antithrombotic) efficacy were evaluated in beagle dog model of arterial thrombosis." | 2.79 | Preparation and evaluation of oral controlled-release cilostazol formulation: pharmacokinetics and antithrombotic efficacy in dogs and healthy male Korean participants. ( Park, JW; Shin, KH; Yoon, G; Yoon, IS, 2014) |
| "Cilostazol is a selective PDE III inhibitor used as antiplatelet agent through cAMP response element-binding (CREB) protein phosphorylation pathway (cAMP/CREB)." | 1.72 | Phosphodiesterase (PDE) III inhibitor, Cilostazol, improved memory impairment in aluminum chloride-treated rats: modulation of cAMP/CREB pathway. ( Abdelsalam, RM; Khalifa, M; Safar, MM; Zaki, HF, 2022) |
| "Cilostazol (CSZ) has been shown to be a new treatment for cognitive impairment with limited efficacy." | 1.72 | Advancing combination treatment with cilostazol and caffeine for Alzheimer's disease in high fat-high fructose-STZ induced model of amnesia. ( Ahmed, AM; El-Mokhtar, MA; Farghaly, HSM; Gomaa, AA; Hemida, FK, 2022) |
| "Cilostazol is a drug of choice for the treatment of intermittent claudication that also affects innate and adaptive immune cells." | 1.56 | Cilostazol Mediates Immune Responses and Affects Angiogenesis During the Acute Phase of Hind Limb Ischemia in a Mouse Model. ( Bouziotis, P; Kadoglou, NPE; Kakisis, I; Katsimpoulas, M; Kostomitsopoulos, NG; Kostopoulos, IV; Lazaris, A; Paronis, E; Poulaki, E; Prignon, A; Provost, C; Spyropoulos, C; Stasinopoulou, M; Tsitsilonis, O, 2020) |
| "Methods- Focal cerebral ischemia was induced by transient middle cerebral artery occlusion in 6- to 8-week-old male C57Bl/6 wild-type mice receiving substance V or vehicle 1 hour after ischemia induction." | 1.51 | Description of a Novel Phosphodiesterase (PDE)-3 Inhibitor Protecting Mice From Ischemic Stroke Independent From Platelet Function. ( Bieber, M; Kleinschnitz, C; Kraft, P; Kumar, GJ; Nieswandt, B; Pham, M; Schuhmann, MK; Stoll, G; Vaidya, JR; Volz, J, 2019) |
| "Levosimendan has vasorelaxant and anti-aggregatory properties." | 1.48 | Cardioprotective and Anti-Aggregatory Effects of Levosimendan on Isoproterenol-Induced Myocardial Injury in High-Fat-Fed Rats Involves Modulation of PI3K/Akt/mTOR Signaling Pathway and Inhibition of Apoptosis: Comparison to Cilostazol. ( El-Kherbetawy, MK; Makary, S; Tawfik, MK, 2018) |
| "Cilostazol treatment reduced the impairment in working memory and white matter function after hypoperfusion." | 1.46 | Long-term cilostazol treatment reduces gliovascular damage and memory impairment in a mouse model of chronic cerebral hypoperfusion. ( Binnie, M; Duncombe, J; Horsburgh, K; Ihara, M; Jansen, M; Kalaria, RN; Kitamura, A; Koudelka, J; Lennen, R; Manso, Y; Marshall, I; Searcy, J; Webster, S, 2017) |
| " Long-term administration of cilostazol restored the impaired context-dependent conditioned fear memory of SAMP8 to match that in normal aging control substrain SAMR1." | 1.46 | Long-term cilostazol administration ameliorates memory decline in senescence-accelerated mouse prone 8 (SAMP8) through a dual effect on cAMP and blood-brain barrier. ( Endo, S; Ishiwata, K; Ito, H; Toyohara, J; Yanai, S, 2017) |
| "Cilostazol(CTL) is a phosphodiesterase inhibitor, which has been widely used as anti-platelet agent." | 1.43 | Neuroprotection of Cilostazol against ischemia/reperfusion-induced cognitive deficits through inhibiting JNK3/caspase-3 by enhancing Akt1. ( Li, M; Liu, F; Liu, P; Ma, JY; Mei, XY; Miu, JC; Qi, DS; Qu, R; Tao, JH; Wang, M; Zhang, F; Zhang, LQ; Zhang, SC, 2016) |
| "Cilostazol treatment improved BBB permeability and reduced gait disturbance, visual impairment and microglial activation in optic tract following BCCAO in vivo." | 1.43 | Cilostazol reduces blood brain barrier dysfunction, white matter lesion formation and motor deficits following chronic cerebral hypoperfusion. ( Cadonic, R; Edrissi, H; Hakim, AM; Schock, SC; Thompson, CS, 2016) |
| "Cilostazol has been shown to be beneficial for the improvement of pain-free walking distance in patients with intermittent claudication in a series of randomized clinical trials." | 1.43 | Induction of Angiogenesis by a Type III Phosphodiesterase Inhibitor, Cilostazol, Through Activation of Peroxisome Proliferator-Activated Receptor-γ and cAMP Pathways in Vascular Cells. ( Carracedo, M; Ikeda-Iwabu, Y; Kanbara, Y; Morishita, R; Muratsu, J; Otsu, R; Rakugi, H; Sanada, F; Sugimoto, K; Taniyama, Y; Yamamoto, K, 2016) |
| "Cilostazol has been reported to alleviate the metabolic syndrome induced by increased intracellular adenosine 3',5'-cyclic monophosphate (cAMP) levels, which is also associated with osteoclast (OC) differentiation." | 1.42 | Cilostazol attenuates ovariectomy-induced bone loss by inhibiting osteoclastogenesis. ( Choi, HS; Chung, HT; Joe, Y; Ke, K; Safder, AM; Suh, JH; Sul, OJ, 2015) |
| "Cilostazol treatment significantly reduced the percentage of 8-OHdG-positive neurons (65." | 1.42 | Neuroprotective effects of cilostazol are mediated by multiple mechanisms in a mouse model of permanent focal ischemia. ( Abumiya, T; Hokari, M; Houkin, K; Kazumata, K; Kuroda, S; Nakayama, N; Shichinohe, H; Tan, C, 2015) |
| "Sildenafil failed to prevent CCH-induced retrograde amnesia, but it reduced hippocampal cell death." | 1.42 | Cilostazol but not sildenafil prevents memory impairment after chronic cerebral hypoperfusion in middle-aged rats. ( Bacarin, CC; de Oliveira, JN; de Oliveira, RM; Ferreira, ED; Godinho, J; Milani, H; Zaghi, GG, 2015) |
| "Intermittent claudication is a form of exercise intolerance characterized by muscle pain during walking in patients with peripheral artery disease (PAD)." | 1.40 | Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice. ( Alcantara, R; Baltgalvis, KA; Claypool, MD; Friera, AM; Godinez, G; Goff, D; Gururaja, T; Hansen, D; Hitoshi, Y; Jenkins, Y; Kinsella, TM; Lang, W; Lau, D; Li, W; Li, Y; Markovtsov, V; McCaughey, K; McLaughlin, J; Nguyen, H; Pan, A; Park, G; Payan, DG; Shaw, SJ; Singh, BK; Singh, R; Smith, IJ; Sun, TQ; Uy, G; White, K, 2014) |
| "Cilostazol is a phosphodiesterase inhibitor that has anti-inflammatory potential in addition to vasodilator and antiplatelet effects." | 1.40 | Effects of cilostazol on oxidative stress, systemic cytokine release, and spinal cord injury in a rat model of transient aortic occlusion. ( Basoglu, H; Cetin, NK; Discigil, B; Kurtoglu, T; Ozkisacik, EA; Tataroglu, C; Yenisey, C, 2014) |
| "Hypothermia has been reported to induce ventricular tachycardia and fibrillation (VT/VF) in patients with early repolarization (ER) pattern." | 1.40 | Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone. ( Antzelevitch, C; Gurabi, Z; Koncz, I; Nesterenko, VV; Patocskai, B, 2014) |
| "Stroke is the major cause of death and decrease in the activities of daily living." | 1.40 | Neurovascular protection of cilostazol in stroke-prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation. ( Abe, K; Deguchi, K; Ikeda, Y; Kono, S; Kurata, T; Liu, N; Liu, W; Omote, Y; Yamashita, T, 2014) |
| "Cilostazol is known to be a selective inhibitor of phosphodiesterase 3 and is generally used to treat intermittent claudication caused by peripheral arterial disease." | 1.38 | Cilostazol stimulates revascularisation in response to ischaemia via an eNOS-dependent mechanism. ( Hori, A; Komori, K; Morisaki, K; Murohara, T; Shibata, R, 2012) |
| "Nimodipine is a calcium channel blocker and is still used in vasospasm therapy either oral or intravenously." | 1.37 | Comparison of intrathecal cilostazol and nimodipine treatments in subarachnoid hemorrhage: an experimental study in rabbits. ( Bilginer, B; Narin, F; Onal, MB; Ozgen, T; Soylemezoglu, F; Ziyal, MI, 2011) |
| "Cilostazol is known to be a specific type III phosphodiesterase inhibitor, which promotes increased intracellular cAMP levels." | 1.36 | Cilostazol enhances neovascularization in the mouse hippocampus after transient forebrain ischemia. ( Hong, KW; Kim, CD; Lee, DH; Lee, HR; Lee, JH; Lee, JS; Lee, SJ; Lee, WS; Park, SY; Rhim, BY; Shin, HK, 2010) |
| "We investigated these effects on cerebral vasospasm after rat SAH." | 1.36 | Cilostazol attenuates cerebral vasospasm after experimental subarachnoid hemorrhage. ( Fujinaka, T; Nishino, A; Umegaki, M; Yoshimine, T, 2010) |
| "Cilostazol is a specific phosphodiesterase III inhibitor." | 1.36 | Suppression of encephalitogenic T-cell responses by cilostazol is associated with upregulation of regulatory T cells. ( Han, Y; Wang, S; Xu, H; Yan, C; Zhao, X, 2010) |
| "Pretreatment with cilostazol significantly attenuated the increased migration of monocytes, possibly through suppression of platelet-monocyte interactions." | 1.35 | Cilostazol, a specific PDE-3 inhibitor, ameliorates chronic ileitis via suppression of interaction of platelets with monocytes. ( Higashiyama, M; Hokari, R; Kawaguchi, A; Komoto, S; Kurihara, C; Matsunaga, H; Miura, S; Nagao, S; Nakamura, M; Okada, Y; Watanabe, C, 2009) |
| "Cilostazol is a potent type III phosphodiesterase inhibitor, approved as an anti-platelet aggregation agent." | 1.35 | Activation of tyrosine hydroxylase prevents pneumonia in a rat chronic cerebral hypoperfusion model. ( Hattori, N; Miyamoto, N; Mochizuki, H; Tanaka, R; Urabe, T; Zhang, N, 2009) |
| "Cilostazol is a hopeful choice for the treatment of multiple sclerosis." | 1.35 | Selective phosphodiesterase-3 inhibitor cilostazol ameliorates experimental autoimmune encephalomyelitis. ( Kureshiro, J; Kusunoki, S; Miyamoto, K; Tanaka, N, 2009) |
| "Cilostazol was administered for 6 days orally 1 day after compression treatment group (n = 6); the nontreatment group (n = 6) did not receive any drug." | 1.35 | The effects of cilostazol on nerve conduction velocity and blood flow: acute and chronic cauda equina compression in a canine model. ( Aoki, Y; Kikuchi, S; Konno, S; Sekiguchi, M, 2008) |
| "Cilostazol was given to group 2 orally on days 28-90." | 1.35 | Cilostazol therapy attenuates monocrotaline-induced pulmonary arterial hypertension in rat model. ( Chang, LT; Chiang, CH; Lee, FY; Sheu, JJ; Sun, CK; Wu, CJ; Yip, HK; Youssef, AA, 2008) |
| "In the present study, cerebral ischemia was induced by a 10 min transient bilateral common carotid artery occlusion in rats combined with arterial blood pressure lowering to 37-42 mm Hg during occlusion." | 1.35 | Cilostazol preserves CA1 hippocampus and enhances generation of immature neuroblasts in dentate gyrus after transient forebrain ischemia in rats. ( Hong, KW; Kim, CD; Lee, JH; Lee, WS; Park, SY; Shin, HK, 2009) |
| "Post-treatment with cilostazol (60 mg kg(-1) day(-1)) strongly suppressed not only elevated activation of astroglia and microglia but also diminished oligodendrocytes following chronic cerebral hypoperfusion." | 1.33 | Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion. ( Hong, KW; Kim, CD; Kim, KY; Lee, JH; Lee, WS; Park, SY; Shin, YW; Sung, SM, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.76) | 18.7374 |
| 1990's | 2 (1.52) | 18.2507 |
| 2000's | 22 (16.67) | 29.6817 |
| 2010's | 94 (71.21) | 24.3611 |
| 2020's | 13 (9.85) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 3 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Luhach, K | 1 |
| Kulkarni, GT | 1 |
| Singh, VP | 1 |
| Sharma, B | 1 |
| Sahin, M | 1 |
| Baytaroglu, C | 1 |
| Sevgili, E | 1 |
| Gomaa, AA | 1 |
| Farghaly, HSM | 1 |
| Ahmed, AM | 1 |
| El-Mokhtar, MA | 1 |
| Hemida, FK | 1 |
| Khalifa, M | 1 |
| Abdelsalam, RM | 1 |
| Safar, MM | 2 |
| Zaki, HF | 2 |
| Li, J | 3 |
| Xiang, X | 2 |
| Xu, H | 2 |
| Shi, Y | 1 |
| Lee, HR | 3 |
| Park, KY | 4 |
| Jeong, YJ | 1 |
| Heo, TH | 4 |
| Paronis, E | 1 |
| Katsimpoulas, M | 1 |
| Kadoglou, NPE | 1 |
| Provost, C | 1 |
| Stasinopoulou, M | 1 |
| Spyropoulos, C | 1 |
| Poulaki, E | 1 |
| Prignon, A | 1 |
| Kakisis, I | 1 |
| Kostomitsopoulos, NG | 1 |
| Bouziotis, P | 1 |
| Kostopoulos, IV | 1 |
| Tsitsilonis, O | 1 |
| Lazaris, A | 1 |
| Tanaka, M | 1 |
| Saito, S | 2 |
| Inoue, T | 2 |
| Satoh-Asahara, N | 1 |
| Ihara, M | 4 |
| Elshazly, SM | 1 |
| Elhassanny, AEM | 1 |
| Mahmoud, NM | 1 |
| Wei, AX | 1 |
| Shao, MY | 1 |
| Liu, Y | 2 |
| Sun, Y | 1 |
| Wang, LM | 1 |
| Ma, XY | 1 |
| Mang, J | 1 |
| Xu, ZX | 1 |
| Gülaştı, ÖF | 1 |
| Yavuz, Ş | 1 |
| Arıkan, AA | 1 |
| Eraldemir, FC | 1 |
| Özbudak, E | 1 |
| Şahin, D | 1 |
| Kır, HM | 1 |
| Kim, SK | 3 |
| Kim, G | 1 |
| Choi, BH | 1 |
| Ryu, D | 1 |
| Ku, SK | 1 |
| Kwak, MK | 1 |
| Shimatani, K | 1 |
| Sato, H | 1 |
| Saito, A | 1 |
| Sasai, M | 1 |
| Watanabe, K | 1 |
| Mizukami, K | 1 |
| Kamohara, M | 1 |
| Miyagawa, S | 1 |
| Sawa, Y | 1 |
| Inan, B | 1 |
| Sönmez Ergün, S | 1 |
| Nurten, A | 1 |
| Küçükgergin, C | 1 |
| Zengin Türkmen, A | 1 |
| Seçkin, Ş | 1 |
| Erkalp, K | 1 |
| Ziyade, S | 1 |
| Imai, T | 1 |
| Matsukawa, H | 1 |
| Takagi, T | 1 |
| Tsuruma, K | 2 |
| Shimazawa, M | 2 |
| Hara, H | 3 |
| Kitamura, A | 2 |
| Manso, Y | 1 |
| Duncombe, J | 1 |
| Searcy, J | 1 |
| Koudelka, J | 1 |
| Binnie, M | 1 |
| Webster, S | 1 |
| Lennen, R | 1 |
| Jansen, M | 1 |
| Marshall, I | 1 |
| Kalaria, RN | 1 |
| Horsburgh, K | 1 |
| Nagai, N | 1 |
| Deguchi, S | 1 |
| Otake, H | 1 |
| Hiramatsu, N | 1 |
| Yamamoto, N | 2 |
| Christensen, SL | 1 |
| Petersen, S | 1 |
| Sørensen, DB | 1 |
| Olesen, J | 1 |
| Jansen-Olesen, I | 1 |
| Miyata, T | 1 |
| Tajima, H | 1 |
| Hirata, M | 1 |
| Nakanuma, SI | 1 |
| Makino, I | 1 |
| Hayashi, H | 1 |
| Oyama, K | 1 |
| Miyashita, T | 2 |
| Takamura, H | 1 |
| Ninomiya, I | 1 |
| Fushida, S | 1 |
| Iseki, S | 1 |
| Harada, SI | 1 |
| Wakayama, T | 1 |
| Ohta, T | 1 |
| Chancharoenthana, W | 1 |
| Leelahavanichkul, A | 1 |
| Taratummarat, S | 1 |
| Wongphom, J | 1 |
| Tiranathanagul, K | 1 |
| Eiam-Ong, S | 1 |
| Hedya, SA | 1 |
| Bahgat, AK | 1 |
| Umebayashi, R | 1 |
| Uchida, HA | 1 |
| Kakio, Y | 1 |
| Subramanian, V | 1 |
| Daugherty, A | 2 |
| Wada, J | 1 |
| Suzuki, T | 1 |
| Kamio, Y | 1 |
| Makino, H | 1 |
| Hokamura, K | 1 |
| Kimura, T | 2 |
| Yamasaki, T | 1 |
| Hiramatsu, H | 1 |
| Umemura, K | 1 |
| Namba, H | 2 |
| Tawfik, MK | 1 |
| El-Kherbetawy, MK | 1 |
| Makary, S | 1 |
| Chen, WJ | 1 |
| Chen, YH | 1 |
| Hsu, YJ | 2 |
| Lin, KH | 1 |
| Yeh, YH | 1 |
| Pazio, A | 1 |
| Santos, VB | 1 |
| Salles Junior, GS | 1 |
| Coelho da Mota, DS | 1 |
| Sicuro, FL | 1 |
| Resende, AC | 1 |
| De Moura, RS | 1 |
| Bottino, DA | 1 |
| Bouskela, E | 1 |
| Kayano, R | 1 |
| Morofuji, Y | 1 |
| Nakagawa, S | 1 |
| Fukuda, S | 2 |
| Watanabe, D | 1 |
| Ozawa, H | 1 |
| Niwa, M | 1 |
| Matsuo, T | 1 |
| Reddy, SS | 1 |
| Agarwal, H | 1 |
| Barthwal, MK | 1 |
| El-Abhar, H | 1 |
| Abd El Fattah, MA | 1 |
| Wadie, W | 1 |
| El-Tanbouly, DM | 1 |
| Hafez, HM | 1 |
| Ibrahim, MA | 1 |
| Zedan, MZ | 1 |
| Hassan, M | 1 |
| Hassanein, H | 1 |
| Sugimoto, K | 2 |
| Nomura, S | 1 |
| Shirao, S | 1 |
| Ishihara, H | 1 |
| Kawano, R | 1 |
| Kawano, A | 1 |
| Oka, F | 1 |
| Suehiro, E | 1 |
| Sadahiro, H | 1 |
| Shinoyama, M | 1 |
| Oku, T | 1 |
| Maruta, Y | 1 |
| Hirayama, Y | 1 |
| Hiyoshi, K | 1 |
| Kiyohira, M | 1 |
| Yoneda, H | 1 |
| Okazaki, K | 1 |
| Dreier, JP | 1 |
| Suzuki, M | 1 |
| Bieber, M | 1 |
| Schuhmann, MK | 1 |
| Volz, J | 1 |
| Kumar, GJ | 1 |
| Vaidya, JR | 1 |
| Nieswandt, B | 1 |
| Pham, M | 1 |
| Stoll, G | 1 |
| Kleinschnitz, C | 1 |
| Kraft, P | 1 |
| Davis, FM | 1 |
| Lu, HS | 1 |
| Cho, O | 2 |
| Jang, YJ | 1 |
| Park, SY | 7 |
| Kim, HY | 4 |
| Lee, YS | 1 |
| Heo, HJ | 1 |
| Shin, HK | 6 |
| Lee, WS | 6 |
| Hong, KW | 9 |
| Kim, CD | 7 |
| Kim, HS | 1 |
| Xu, Z | 1 |
| Tanaka, H | 1 |
| Zaima, N | 1 |
| Ito, H | 4 |
| Hattori, K | 1 |
| Konno, H | 1 |
| Setou, M | 1 |
| Unno, N | 1 |
| Maiga, M | 2 |
| Ammerman, NC | 2 |
| Maiga, MC | 2 |
| Tounkara, A | 1 |
| Siddiqui, S | 1 |
| Polis, M | 1 |
| Murphy, R | 1 |
| Bishai, WR | 2 |
| Souza Júnior, SS | 2 |
| Moreira Neto, AA | 2 |
| Schmidt Júnior, AF | 2 |
| Lemos, JB | 1 |
| Rodrigues, OR | 2 |
| Szél, T | 1 |
| Koncz, I | 3 |
| Antzelevitch, C | 3 |
| Yamamoto, S | 1 |
| Kurokawa, R | 1 |
| Kim, P | 1 |
| Fukuoka, T | 1 |
| Hayashi, T | 1 |
| Hirayama, M | 1 |
| Maruyama, H | 1 |
| Tanahashi, N | 1 |
| Omote, Y | 1 |
| Deguchi, K | 1 |
| Kono, S | 1 |
| Liu, N | 1 |
| Liu, W | 1 |
| Kurata, T | 1 |
| Yamashita, T | 2 |
| Ikeda, Y | 1 |
| Abe, K | 1 |
| Gurabi, Z | 2 |
| Patocskai, B | 2 |
| Nesterenko, VV | 1 |
| Kurtoglu, T | 1 |
| Basoglu, H | 1 |
| Ozkisacik, EA | 1 |
| Cetin, NK | 1 |
| Tataroglu, C | 1 |
| Yenisey, C | 1 |
| Discigil, B | 1 |
| Hamazaki, TS | 1 |
| Sugaya, M | 1 |
| Chan, T | 1 |
| Tamura-Nakano, M | 1 |
| Sato, S | 1 |
| Okochi, H | 1 |
| Baltgalvis, KA | 1 |
| White, K | 1 |
| Claypool, MD | 1 |
| Lang, W | 1 |
| Alcantara, R | 1 |
| Singh, BK | 1 |
| Friera, AM | 1 |
| McLaughlin, J | 1 |
| Hansen, D | 1 |
| McCaughey, K | 1 |
| Nguyen, H | 1 |
| Smith, IJ | 1 |
| Godinez, G | 1 |
| Shaw, SJ | 1 |
| Goff, D | 1 |
| Singh, R | 1 |
| Markovtsov, V | 1 |
| Sun, TQ | 1 |
| Jenkins, Y | 1 |
| Uy, G | 1 |
| Li, Y | 1 |
| Pan, A | 1 |
| Gururaja, T | 1 |
| Lau, D | 1 |
| Park, G | 1 |
| Hitoshi, Y | 1 |
| Payan, DG | 1 |
| Kinsella, TM | 1 |
| Matsumoto, S | 1 |
| Watanabe, M | 1 |
| Hashizume, K | 1 |
| Wada, N | 1 |
| Hori, J | 1 |
| Kita, M | 1 |
| Iwata, T | 1 |
| Kakizaki, H | 1 |
| Shin, KH | 1 |
| Yoon, G | 1 |
| Yoon, IS | 1 |
| Park, JW | 2 |
| Kwon, KJ | 2 |
| Lee, EJ | 1 |
| Kim, MK | 1 |
| Kim, SY | 1 |
| Kim, JN | 1 |
| Kim, JO | 1 |
| Kim, HJ | 3 |
| Han, JS | 2 |
| Shin, CY | 2 |
| Han, SH | 2 |
| Nazli, Y | 1 |
| Colak, N | 1 |
| Namuslu, M | 1 |
| Erdamar, H | 1 |
| Haltas, H | 1 |
| Alpay, MF | 1 |
| Nuri Aksoy, O | 1 |
| Olgun Akkaya, I | 1 |
| Cakir, O | 1 |
| Shichinohe, H | 1 |
| Tan, C | 1 |
| Abumiya, T | 1 |
| Nakayama, N | 1 |
| Kazumata, K | 1 |
| Hokari, M | 1 |
| Houkin, K | 1 |
| Kuroda, S | 1 |
| Godinho, J | 1 |
| de Oliveira, JN | 1 |
| Ferreira, ED | 1 |
| Zaghi, GG | 1 |
| Bacarin, CC | 1 |
| de Oliveira, RM | 1 |
| Milani, H | 1 |
| Zhao, Z | 1 |
| Wang, X | 1 |
| Chen, Y | 3 |
| Yang, W | 1 |
| Cheng, L | 1 |
| Liu, E | 1 |
| Liu, T | 1 |
| Li, G | 1 |
| Joe, Y | 3 |
| Zheng, M | 1 |
| Uddin, MJ | 1 |
| Park, J | 3 |
| Cho, GJ | 2 |
| Ryter, SW | 2 |
| Chung, HT | 3 |
| Ke, K | 1 |
| Safder, AM | 1 |
| Sul, OJ | 1 |
| Suh, JH | 1 |
| Choi, HS | 2 |
| Tara, S | 1 |
| Kurobe, H | 1 |
| de Dios Ruiz Rosado, J | 1 |
| Best, CA | 1 |
| Shoji, T | 1 |
| Mahler, N | 1 |
| Yi, T | 1 |
| Lee, YU | 1 |
| Sugiura, T | 1 |
| Hibino, N | 1 |
| Partida-Sanchez, S | 1 |
| Breuer, CK | 1 |
| Shinoka, T | 1 |
| Shiga, T | 1 |
| Sahara, H | 1 |
| Orito, K | 1 |
| Choi, BR | 1 |
| Kim, DH | 1 |
| Back, DB | 1 |
| Kang, CH | 1 |
| Moon, WJ | 1 |
| Choi, DH | 1 |
| Kim, BR | 1 |
| Lee, J | 1 |
| Kim, YR | 2 |
| Kim, HN | 2 |
| Choi, BT | 2 |
| Sanada, F | 1 |
| Kanbara, Y | 1 |
| Taniyama, Y | 1 |
| Otsu, R | 1 |
| Carracedo, M | 1 |
| Ikeda-Iwabu, Y | 1 |
| Muratsu, J | 1 |
| Yamamoto, K | 1 |
| Rakugi, H | 1 |
| Morishita, R | 1 |
| Barajas-Martinez, H | 1 |
| Hu, D | 1 |
| Manousopoulou, A | 1 |
| Yamamoto, Y | 1 |
| Al-Daghri, NM | 1 |
| Carare, RO | 1 |
| Garbis, SD | 1 |
| Pandiri, I | 1 |
| Ryu, J | 1 |
| Edrissi, H | 1 |
| Schock, SC | 1 |
| Cadonic, R | 1 |
| Hakim, AM | 1 |
| Thompson, CS | 1 |
| El-Dessouki, AM | 1 |
| Galal, MA | 1 |
| Awad, AS | 1 |
| Qi, DS | 1 |
| Tao, JH | 1 |
| Zhang, LQ | 1 |
| Li, M | 1 |
| Wang, M | 1 |
| Qu, R | 1 |
| Zhang, SC | 1 |
| Liu, P | 1 |
| Liu, F | 1 |
| Miu, JC | 1 |
| Ma, JY | 1 |
| Mei, XY | 1 |
| Zhang, F | 1 |
| Lee, CH | 1 |
| Hung, YJ | 1 |
| Shieh, YS | 1 |
| Chien, CY | 1 |
| Lin, CY | 1 |
| Chiang, CF | 1 |
| Huang, CL | 1 |
| Hsieh, CH | 1 |
| Tsukamoto, Y | 1 |
| Nagata, E | 1 |
| Fukuyama, N | 1 |
| Itoh, Y | 1 |
| Yuzawa, H | 1 |
| Kohara, S | 1 |
| Shimizu, M | 1 |
| Takahari, Y | 1 |
| Takizawa, S | 1 |
| Yanai, S | 1 |
| Toyohara, J | 1 |
| Ishiwata, K | 1 |
| Endo, S | 1 |
| He, P | 1 |
| Kawamura, H | 1 |
| Takemoto, M | 1 |
| Maezawa, Y | 1 |
| Ishikawa, T | 1 |
| Ishibashi, R | 1 |
| Sakamoto, K | 1 |
| Shoji, M | 1 |
| Hattori, A | 1 |
| Yamaga, M | 1 |
| Ide, S | 1 |
| Ide, K | 1 |
| Hayashi, A | 1 |
| Tokuyama, H | 1 |
| Kobayashi, K | 1 |
| Yokote, K | 1 |
| Kangawa, Y | 1 |
| Yoshida, T | 1 |
| Abe, H | 1 |
| Seto, Y | 1 |
| Nakamura, M | 2 |
| Kihara, T | 1 |
| Hayashi, SM | 1 |
| Shibutani, M | 1 |
| Barta, J | 2 |
| Sanganalmath, SK | 2 |
| Kumamoto, H | 2 |
| Takeda, N | 2 |
| Edes, I | 1 |
| Dhalla, NS | 2 |
| Lee, JH | 3 |
| Sekiguchi, M | 1 |
| Aoki, Y | 1 |
| Konno, S | 1 |
| Kikuchi, S | 1 |
| Zhang, N | 1 |
| Miyamoto, N | 2 |
| Tanaka, R | 3 |
| Mochizuki, H | 1 |
| Hattori, N | 3 |
| Urabe, T | 3 |
| Mendes, JB | 1 |
| Campos, PP | 1 |
| Rocha, MA | 1 |
| Andrade, SP | 1 |
| Nonaka, Y | 1 |
| Yoshimura, S | 1 |
| Iwama, T | 1 |
| Kureshiro, J | 1 |
| Miyamoto, K | 1 |
| Tanaka, N | 1 |
| Kusunoki, S | 1 |
| Yamaguchi-Okada, M | 1 |
| Nishizawa, S | 1 |
| Mizutani, A | 1 |
| Shimosawa, T | 1 |
| Yatomi, Y | 1 |
| Fujita, T | 1 |
| Matsunaga, H | 1 |
| Hokari, R | 1 |
| Higashiyama, M | 1 |
| Kurihara, C | 1 |
| Okada, Y | 1 |
| Watanabe, C | 1 |
| Komoto, S | 1 |
| Kawaguchi, A | 1 |
| Nagao, S | 1 |
| Miura, S | 1 |
| Bilginer, B | 2 |
| Onal, MB | 2 |
| Narin, F | 2 |
| Soylemezoglu, F | 2 |
| Ziyal, IM | 1 |
| Ozgen, T | 2 |
| Sakurada, M | 1 |
| Yoshimoto, T | 1 |
| Sekizawa, N | 1 |
| Hirono, Y | 1 |
| Suzuki, N | 1 |
| Hirata, Y | 1 |
| Lee, DH | 2 |
| Lee, SJ | 1 |
| Lee, JS | 1 |
| Rhim, BY | 3 |
| Kim, SH | 2 |
| Chang, HW | 1 |
| Choi, TH | 1 |
| Kim, JH | 3 |
| Son, D | 1 |
| Han, K | 1 |
| Lee, SY | 3 |
| Suh, EH | 1 |
| Park, SH | 1 |
| Nishino, A | 1 |
| Umegaki, M | 1 |
| Fujinaka, T | 1 |
| Yoshimine, T | 1 |
| Wang, S | 1 |
| Yan, C | 1 |
| Zhao, X | 1 |
| Han, Y | 1 |
| Hiramatsu, M | 1 |
| Takiguchi, O | 1 |
| Nishiyama, A | 1 |
| Mori, H | 1 |
| Tanaka, Y | 1 |
| Liu, M | 1 |
| Ziyal, MI | 1 |
| Kim, EK | 1 |
| Bae, SS | 1 |
| Ishiguro, M | 1 |
| Zhang, Q | 1 |
| Ye, YL | 1 |
| Li, Q | 1 |
| Zhang, WP | 1 |
| Jiang, LL | 1 |
| Wei, EQ | 1 |
| Yu, YP | 1 |
| Al-Qudah, ZA | 1 |
| Hassan, AE | 1 |
| Qureshi, AI | 1 |
| Bai, Y | 1 |
| Murakami, H | 1 |
| Iwasa, M | 1 |
| Sumi, S | 1 |
| Yamada, Y | 1 |
| Ushikoshi, H | 1 |
| Aoyama, T | 1 |
| Nishigaki, K | 1 |
| Takemura, G | 1 |
| Uno, B | 1 |
| Minatoguchi, S | 1 |
| Takeda, M | 1 |
| Shinohara, M | 1 |
| Sasaki, N | 1 |
| Tawa, H | 1 |
| Nakajima, K | 1 |
| Momose, A | 1 |
| Hirata, K | 1 |
| Hori, A | 1 |
| Shibata, R | 1 |
| Morisaki, K | 1 |
| Murohara, T | 1 |
| Komori, K | 1 |
| Hase, Y | 1 |
| Okamoto, Y | 1 |
| Fujita, Y | 1 |
| Nakabayashi, H | 1 |
| Maki, T | 1 |
| Washida, K | 1 |
| Takahashi, R | 1 |
| Takigawa, T | 1 |
| Tsurushima, H | 1 |
| Suzuki, K | 1 |
| Tsuruta, W | 1 |
| Nakamura, K | 1 |
| Matsumura, A | 1 |
| Jung, IH | 1 |
| Lee, YH | 1 |
| Yoo, JY | 1 |
| Jeong, SJ | 1 |
| Sonn, SK | 1 |
| Park, JG | 1 |
| Ryu, KH | 1 |
| Lee, BY | 1 |
| Han, HY | 1 |
| Kim, DY | 1 |
| Lee, H | 1 |
| Oh, GT | 1 |
| Agarwal, N | 1 |
| Gupta, R | 1 |
| Guo, H | 1 |
| Lun, S | 1 |
| Santos, MR | 1 |
| Celotto, AC | 1 |
| Capellini, VK | 1 |
| Evora, PR | 1 |
| Piccinato, CE | 1 |
| Joviliano, EE | 1 |
| Biscetti, F | 1 |
| Pecorini, G | 1 |
| Straface, G | 1 |
| Arena, V | 1 |
| Stigliano, E | 1 |
| Rutella, S | 1 |
| Locatelli, F | 1 |
| Angelini, F | 1 |
| Ghirlanda, G | 1 |
| Flex, A | 1 |
| Ashitate, Y | 1 |
| Tanaka, E | 1 |
| Henary, M | 1 |
| Frangioni, JV | 1 |
| Flaumenhaft, R | 1 |
| Lee, SW | 3 |
| Baek, SH | 2 |
| Lee, CW | 2 |
| Birnbaum, Y | 2 |
| Castillo, AC | 2 |
| Qian, J | 2 |
| Ling, S | 2 |
| Ye, H | 2 |
| Perez-Polo, JR | 2 |
| Bajaj, M | 2 |
| Ye, Y | 2 |
| Capelozzi, VL | 1 |
| Parra-Cuentas, ER | 1 |
| Francisco Neto, A | 1 |
| Tanano, I | 1 |
| Nagaoka, T | 1 |
| Omae, T | 1 |
| Ishibazawa, A | 1 |
| Kamiya, T | 1 |
| Ono, S | 1 |
| Yoshida, A | 1 |
| Park, KH | 1 |
| Jeong, MH | 1 |
| Kim, JM | 1 |
| Park, DS | 1 |
| Lim, KS | 1 |
| Lee, KH | 1 |
| Sim, DS | 1 |
| Yoon, HJ | 1 |
| Yoon, NS | 1 |
| Kim, KH | 1 |
| Park, HW | 1 |
| Hong, YJ | 1 |
| Ahn, Y | 1 |
| Cho, JG | 1 |
| Park, JC | 1 |
| Kang, JC | 1 |
| Nakai, K | 1 |
| Takenobu, Y | 1 |
| Takimizu, H | 1 |
| Akimaru, S | 1 |
| Maegawa, H | 1 |
| Marsala, M | 1 |
| Katsube, N | 1 |
| Li, H | 1 |
| Cone, J | 1 |
| Fong, M | 1 |
| Kambayashi, J | 1 |
| Yoshitake, M | 1 |
| Honda, F | 1 |
| Imai, H | 1 |
| Ishikawa, M | 1 |
| Kubota, C | 1 |
| Shimizu, T | 1 |
| Fukunaga, M | 1 |
| Saito, N | 1 |
| Ohba, R | 2 |
| Otaka, M | 2 |
| Odashima, M | 2 |
| Jin, M | 2 |
| Komatsu, K | 1 |
| Konishi, N | 1 |
| Wada, I | 2 |
| Horikawa, Y | 2 |
| Matsuhashi, T | 2 |
| Oyake, J | 2 |
| Hatakeyama, N | 2 |
| Watanabe, S | 2 |
| Shin, YW | 1 |
| Sung, SM | 1 |
| Kim, KY | 1 |
| Zhao, H | 1 |
| Quilley, J | 1 |
| Montrose, DC | 1 |
| Rajagopalan, S | 1 |
| Guan, Q | 1 |
| Smith, CJ | 1 |
| Song, YS | 1 |
| Shin, SH | 1 |
| Kim, KT | 1 |
| Park, YC | 1 |
| Park, BS | 1 |
| Yun, I | 1 |
| Kim, K | 1 |
| Chung, WT | 1 |
| Lee, HJ | 1 |
| Yoo, YH | 1 |
| Chang, LT | 1 |
| Sun, CK | 1 |
| Sheu, JJ | 1 |
| Chiang, CH | 1 |
| Youssef, AA | 1 |
| Lee, FY | 1 |
| Wu, CJ | 1 |
| Yip, HK | 1 |
| Hotta, N | 1 |
| Koh, N | 1 |
| Sakakibara, F | 1 |
| Nakamura, J | 1 |
| Hamada, Y | 1 |
| Hara, T | 1 |
| Mori, K | 1 |
| Naruse, K | 1 |
| Fukasawa, H | 1 |
| Kakuta, H | 1 |
| Sakamoto, N | 1 |
| Kohda, N | 1 |
| Tani, T | 2 |
| Nakayama, S | 1 |
| Adachi, T | 1 |
| Marukawa, K | 1 |
| Ito, R | 1 |
| Ishida, K | 1 |
| Matsumoto, Y | 1 |
| Kimura, Y | 2 |
| Chang, SA | 1 |
| Cha, BY | 1 |
| Yoo, SJ | 1 |
| Ahn, YB | 1 |
| Song, KH | 1 |
| Han, JH | 1 |
| Lee, JM | 1 |
| Son, HS | 1 |
| Yoon, KH | 1 |
| Kang, MI | 1 |
| Lee, KW | 1 |
| Son, HY | 1 |
| Kang, SK | 1 |
| Kawamura, K | 1 |
| Fujita, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Regeneration in Cervical Degenerative Myelopathy - a Multi-centre, Double-blind, Randomised, Placebo Controlled Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy[NCT04631471] | Phase 3 | 400 participants (Anticipated) | Interventional | 2021-12-22 | Recruiting | ||
| Cerebral Aneurysms: a Retrospective Study on the Experience in Our Hospital With a Comparative Analysis Between the Different Techniques Used in Its Treatment[NCT04792944] | 247 participants (Actual) | Observational | 2007-01-01 | Completed | |||
| Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Collateral Formation Assessed by Dual-energy 128-row CT Angiography Mediated Through Multiple Mechanisms in Patients With Mild-to-moderate PAOD[NCT01952756] | Phase 4 | 44 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Endothelial Function Mediated Through Modification of Vasculogenesis and Angiogenesis Factors in Patients With Stable Coronary Artery Disease[NCT02174939] | Phase 4 | 300 participants (Anticipated) | Interventional | 2014-02-28 | Recruiting | ||
| Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells Mediated Through Multiple Mechanisms in Patients With High Risk for Cardiovascular Disease[NCT02194686] | Phase 4 | 71 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| The Phosphodiesterase 3 Inhibitor Cilostazol as Adjunct to Methotrexate in Patients With Rheumatoid Arthritis[NCT05594680] | Phase 3 | 70 participants (Anticipated) | Interventional | 2022-10-01 | Recruiting | ||
| Evaluation of the Effect of Cilostazol on the Clinical Outcomes of Rheumatoid Arthritis Patients[NCT05671497] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for cilostazol and Disease Models, Animal
| Article | Year |
|---|---|
Potential Therapeutic Approaches for Cerebral Amyloid Angiopathy and Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Aspartic Ac | 2020 |
Updates of Recent Aortic Aneurysm Research.
Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Animals; Aortic Aneurysm, Abdominal; | 2019 |
[Protective effects of cilostazol against transient focal cerebral ischemia and hemorrhagic transformation].
Topics: Animals; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Cyclic AMP; Disease Models, Animal; Endoth | 2011 |
2 trials available for cilostazol and Disease Models, Animal
| Article | Year |
|---|---|
Cilostazol decreases duration of spreading depolarization and spreading ischemia after aneurysmal subarachnoid hemorrhage.
Topics: Aged; Animals; Brain Ischemia; Cerebrovascular Circulation; Cilostazol; Cortical Spreading Depressio | 2018 |
Preparation and evaluation of oral controlled-release cilostazol formulation: pharmacokinetics and antithrombotic efficacy in dogs and healthy male Korean participants.
Topics: Administration, Oral; Animals; Cilostazol; Delayed-Action Preparations; Disease Models, Animal; Dogs | 2014 |
127 other studies available for cilostazol and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Cilostazol attenuated prenatal valproic acid-induced behavioural and biochemical deficits in a rat model of autism spectrum disorder.
Topics: Animals; Anticonvulsants; Anxiety; Autism Spectrum Disorder; Behavior, Animal; Biomarkers; Brain; Ci | 2021 |
Cardioprotective Effect of Cilostazol on Ischemia-Reperfusion Injury Model.
Topics: Adenosine Triphosphate; Animals; Cilostazol; Disease Models, Animal; Ischemia; Rats; Rats, Wistar; R | 2022 |
Advancing combination treatment with cilostazol and caffeine for Alzheimer's disease in high fat-high fructose-STZ induced model of amnesia.
Topics: Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Caffeine; Cilostazol; Diabetes Mellitus, | 2022 |
Phosphodiesterase (PDE) III inhibitor, Cilostazol, improved memory impairment in aluminum chloride-treated rats: modulation of cAMP/CREB pathway.
Topics: Acetylcholinesterase; Aluminum Chloride; Alzheimer Disease; Animals; Cilostazol; Cyclic AMP Response | 2022 |
Cilostazol Promotes Angiogenesis and Increases Cell Proliferation After Myocardial Ischemia-Reperfusion Injury Through a cAMP-Dependent Mechanism.
Topics: Angiogenesis Inducing Agents; Animals; Apoptosis; Cell Hypoxia; Cell Proliferation; Cells, Cultured; | 2019 |
Comparative effectiveness of different antiplatelet agents at reducing TNF-driven inflammatory responses in a mouse model.
Topics: Animals; Cilostazol; Clopidogrel; Disease Models, Animal; Inflammation; Inflammation Mediators; Male | 2020 |
Cilostazol Mediates Immune Responses and Affects Angiogenesis During the Acute Phase of Hind Limb Ischemia in a Mouse Model.
Topics: Angiogenesis Inducing Agents; Animals; Cilostazol; Cytokines; Disease Models, Animal; Hindlimb; Immu | 2020 |
Cilostazol protects against acetic acid-induced colitis in rats: Possible role for cAMP/SIRT1 pathway.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents; Cilostazol; Colitis; Colon; Cyclic AMP; Cytoprotecti | 2020 |
Influence of Cilostazol on Changes in Cyclin D1 Expression in Cerebral Cortex of Rats with Chronic Cerebral Ischemia.
Topics: Animals; Brain Ischemia; Cerebral Cortex; Chronic Disease; Cilostazol; Cyclin D1; Disease Models, An | 2020 |
Comparison of Cilostazol and Naftidrofuryl in an Experimental Acute Ischemia-Reperfusion Model.
Topics: Animals; Antioxidants; Biomarkers; Brain; Cilostazol; Disease Models, Animal; Kidney; Liver; Male; M | 2021 |
Negative correlation of urinary miR-199a-3p level with ameliorating effects of sarpogrelate and cilostazol in hypertensive diabetic nephropathy.
Topics: Animals; Biomarkers, Pharmacological; Cilostazol; Diabetic Nephropathies; Disease Models, Animal; Hy | 2021 |
A novel model of chronic limb ischemia to therapeutically evaluate the angiogenic effects of drug candidates.
Topics: Angiogenesis Inducing Agents; Animals; Blood Flow Velocity; Cells, Cultured; Chronic Disease; Cilost | 2021 |
Effects of Cilostazol and Diltiazem Hydrochloride on Ischemia-Reperfusion Injury in a Rat Hindlimb Model.
Topics: Animals; Calcium Channel Blockers; Cilostazol; Diltiazem; Disease Models, Animal; Drug Therapy, Comb | 2017 |
The phosphodiesterase III inhibitor cilostazol protects the brain microvasculature from collagenase injury.
Topics: Administration, Oral; Animals; Brain; Cardiovascular Agents; Cells, Cultured; Cilostazol; Collagen T | 2017 |
Long-term cilostazol treatment reduces gliovascular damage and memory impairment in a mouse model of chronic cerebral hypoperfusion.
Topics: Animals; Brain Ischemia; Cell Adhesion Molecules; Cilostazol; Disease Models, Animal; Dose-Response | 2017 |
Therapeutic Effect of Cilostazol Ophthalmic Nanodispersions on Retinal Dysfunction in Streptozotocin-Induced Diabetic Rats.
Topics: Animals; Cell Line; Cell Survival; Cilostazol; Diabetes Mellitus, Experimental; Diabetic Retinopathy | 2017 |
Cilostazol induces C-fos expression in the trigeminal nucleus caudalis and behavioural changes suggestive of headache with the migraine-like feature photophobia in female rats.
Topics: Animals; Behavior, Animal; Cilostazol; Disease Models, Animal; Female; Migraine Disorders; Proto-Onc | 2018 |
Phosphodiesterase III inhibitor attenuates rat sinusoidal obstruction syndrome through inhibition of platelet aggregation in Disse's space.
Topics: Animals; Antigens, CD34; Capillaries; Cilostazol; Disease Models, Animal; Epithelial Cells; Hepatic | 2018 |
Cilostazol attenuates intimal hyperplasia in a mouse model of chronic kidney disease.
Topics: Animals; Cilostazol; Disease Models, Animal; Hyperplasia; Kidney Failure, Chronic; Mice; Nephrectomy | 2017 |
Cilostazol Mediated Nurr1 and Autophagy Enhancement: Neuroprotective Activity in Rat Rotenone PD Model.
Topics: Animals; Apoptosis; Autophagy; Behavior, Animal; Biomarkers; Cilostazol; Disease Models, Animal; Gly | 2018 |
Cilostazol Attenuates Angiotensin II-Induced Abdominal Aortic Aneurysms but Not Atherosclerosis in Apolipoprotein E-Deficient Mice.
Topics: Angiotensin II; Animals; Anti-Inflammatory Agents; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Ath | 2018 |
Prevention Effect of Antiplatelets on Aneurysm Rupture in a Mouse Intracranial Aneurysm Model.
Topics: Aneurysm, Ruptured; Animals; Aspirin; Cerebral Arteries; Cilostazol; Cyclooxygenase 2; Cyclooxygenas | 2018 |
Cardioprotective and Anti-Aggregatory Effects of Levosimendan on Isoproterenol-Induced Myocardial Injury in High-Fat-Fed Rats Involves Modulation of PI3K/Akt/mTOR Signaling Pathway and Inhibition of Apoptosis: Comparison to Cilostazol.
Topics: Animals; Apoptosis; Cilostazol; Diet, High-Fat; Disease Models, Animal; Heart Rate; Inflammation Med | 2018 |
MicroRNA-132 targeting PTEN contributes to cilostazol-promoted vascular smooth muscle cell differentiation.
Topics: 3' Untranslated Regions; Animals; Binding Sites; Calcium-Binding Proteins; Calponins; Cardiovascular | 2018 |
Effect of cilostazol in experimental model of degloving injuries in rat limbs.
Topics: Animals; Cilostazol; Degloving Injuries; Disease Models, Animal; Humans; Laser-Doppler Flowmetry; Lo | 2018 |
Effects of açaí and cilostazol on skin microcirculation and viability of TRAM flaps in hamsters.
Topics: Animals; Capillaries; Cilostazol; Cricetinae; Disease Models, Animal; Drug Evaluation, Preclinical; | 2018 |
In vitro analysis of drugs that improve hyperglycemia-induced blood-brain barrier dysfunction.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Blood-Brain Barrier; Cilostazol; Disease Models, Animal | 2018 |
Cilostazol ameliorates heart failure with preserved ejection fraction and diastolic dysfunction in obese and non-obese hypertensive mice.
Topics: Angiotensin II; Animals; Biomarkers; Biopsy; Blood Pressure; Cilostazol; Diastole; Disease Models, A | 2018 |
Cilostazol disrupts TLR-4, Akt/GSK-3β/CREB, and IL-6/JAK-2/STAT-3/SOCS-3 crosstalk in a rat model of Huntington's disease.
Topics: Animals; Apoptosis; Cilostazol; Corpus Striatum; CREB-Binding Protein; Cyclic AMP Response Element-B | 2018 |
Nephroprotective effect of cilostazol and verapamil against thioacetamide-induced toxicity in rats may involve Nrf2/HO-1/NQO-1 signaling pathway.
Topics: Animals; Antioxidants; Cilostazol; Cytoprotection; Disease Models, Animal; Heme Oxygenase (Decyclizi | 2019 |
Combination therapy with cilostazol and pravastatin improves antiatherogenic effects in low-density lipoprotein receptor knockout mice.
Topics: Animals; Aorta; Aortic Diseases; Atherosclerosis; Cell Adhesion Molecules; Cholesterol, Dietary; Cil | 2018 |
Description of a Novel Phosphodiesterase (PDE)-3 Inhibitor Protecting Mice From Ischemic Stroke Independent From Platelet Function.
Topics: Animals; Blood Platelets; Blood-Brain Barrier; Brain Ischemia; Cilostazol; Disease Models, Animal; M | 2019 |
Beneficial anti-inflammatory effects of combined rosuvastatin and cilostazol in a TNF-driven inflammatory model.
Topics: Animals; Anti-Inflammatory Agents; Cilostazol; Disease Models, Animal; Drug Therapy, Combination; He | 2019 |
Augmented improvement of cognition and memory by aripiprazole add-on for cilostazol treatment in the chronic cerebral hypoperfusion mouse model.
Topics: Animals; Aripiprazole; Brain; Brain Ischemia; Carotid Stenosis; Cilostazol; Cognition; Cognitive Dys | 2019 |
A Comparison of the Anti-Inflammatory Effects of Four Combined Statin and Antiplatelet Therapies on Tumor Necrosis Factor-Mediated Acute Inflammation in vivo.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Cilostazol; Clopidogrel; Disease Models, An | 2019 |
Cilostazol protects against myocardial ischemia and reperfusion injury by activating transcription factor EB (TFEB).
Topics: Animals; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cilostazol; Disease | 2019 |
Cilostazol inhibits accumulation of triglycerides in a rat model of carotid artery ligation.
Topics: Animals; Cardiovascular Agents; Carotid Artery, Common; Carotid Stenosis; Cholesterol, HDL; Cilostaz | 2013 |
Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment.
Topics: Animals; Antitubercular Agents; Bacterial Load; Cilostazol; Disease Models, Animal; Drug Interaction | 2013 |
Biochemical study of the effects of cilostazol in rats subjected to acute ischemia and reperfusion of hind limbs.
Topics: Animals; Cilostazol; Creatinine; Disease Models, Animal; Hindlimb; Male; Myoglobin; Platelet Aggrega | 2013 |
Cellular mechanisms underlying the effects of milrinone and cilostazol to suppress arrhythmogenesis associated with Brugada syndrome.
Topics: Action Potentials; Animals; Brugada Syndrome; Cilostazol; Disease Models, Animal; Dogs; Drug Therapy | 2013 |
Cilostazol, a selective Type III phosphodiesterase inhibitor: prevention of cervical myelopathy in a rat chronic compression model.
Topics: Animals; Cervical Vertebrae; Cilostazol; Disease Models, Animal; Male; Neurons; Phosphodiesterase 3 | 2014 |
Cilostazol inhibits leukocyte-endothelial cell interactions in murine microvessels after transient bilateral common carotid artery occlusion.
Topics: Animals; Carotid Stenosis; Cilostazol; Disease Models, Animal; Dose-Response Relationship, Drug; End | 2014 |
Neurovascular protection of cilostazol in stroke-prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation.
Topics: Animals; Antigens; Aspirin; Cerebrovascular Circulation; Cilostazol; Clopidogrel; Disease Models, An | 2014 |
Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cilostazol; Disease Models, Animal; Dogs; Electr | 2014 |
Effects of cilostazol on oxidative stress, systemic cytokine release, and spinal cord injury in a rat model of transient aortic occlusion.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aorta, Abdominal; Biomarkers; Cell Survival; Cilost | 2014 |
Cilostazol improves lymphatic function by inducing proliferation and stabilization of lymphatic endothelial cells.
Topics: Animals; Cell Movement; Cell Proliferation; Cells, Cultured; Cilostazol; Disease Models, Animal; Dru | 2014 |
Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice.
Topics: Aging; AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Arginine; Cilostazol; Diet, High-F | 2014 |
Effects of chronic treatment with cilostazol, a phosphodiesterase 3 inhibitor, on female rat bladder in a partial bladder outlet obstruction model.
Topics: Animals; Carbachol; Cilostazol; Disease Models, Animal; Electric Stimulation; Female; Muscle Contrac | 2014 |
Diabetes augments cognitive dysfunction in chronic cerebral hypoperfusion by increasing neuronal cell death: implication of cilostazol for diabetes mellitus-induced dementia.
Topics: Animals; Brain; Brain-Derived Neurotrophic Factor; Carotid Artery Diseases; Caspase 3; Cell Death; C | 2015 |
Cilostazol attenuates spinal cord ischemia-reperfusion injury in rabbits.
Topics: Animals; Cilostazol; Disease Models, Animal; Phosphodiesterase 3 Inhibitors; Prospective Studies; Ra | 2015 |
Neuroprotective effects of cilostazol are mediated by multiple mechanisms in a mouse model of permanent focal ischemia.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Brain; Brain Ischemia; Cilostazol; CREB-Binding Protein; Deoxy | 2015 |
Cilostazol but not sildenafil prevents memory impairment after chronic cerebral hypoperfusion in middle-aged rats.
Topics: Aging; Amnesia, Retrograde; Animals; Brain Ischemia; Carotid Artery Diseases; Carotid Artery, Intern | 2015 |
Cilostazol ameliorates atrial ionic remodeling in long-term rapid atrial pacing dogs.
Topics: Animals; Atrial Remodeling; Cardiac Pacing, Artificial; Cilostazol; Disease Models, Animal; Dogs; Fe | 2015 |
Cilostazol attenuates murine hepatic ischemia and reperfusion injury via heme oxygenase-dependent activation of mitochondrial biogenesis.
Topics: Animals; Cilostazol; Cytoprotection; Disease Models, Animal; DNA-Binding Proteins; Gene Expression R | 2015 |
Cilostazol attenuates ovariectomy-induced bone loss by inhibiting osteoclastogenesis.
Topics: Animals; Bone Density; Cell Differentiation; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Ki | 2015 |
Cilostazol, Not Aspirin, Prevents Stenosis of Bioresorbable Vascular Grafts in a Venous Model.
Topics: Absorbable Implants; Animals; Aspirin; Blood Vessel Prosthesis; Cell Proliferation; Cilostazol; Dise | 2015 |
Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats.
Topics: Angiogenic Proteins; Animals; Carnitine; Cilostazol; Disease Models, Animal; Drug Therapy, Combinati | 2015 |
Characterization of White Matter Injury in a Rat Model of Chronic Cerebral Hypoperfusion.
Topics: Animals; Behavior, Animal; Brain Ischemia; Carotid Stenosis; Chronic Disease; Cilostazol; Cognition; | 2016 |
Anti-depressant effects of phosphodiesterase 3 inhibitor cilostazol in chronic mild stress-treated mice after ischemic stroke.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cilostazol; Corpus Striatum; Cyclic AMP Response Element | 2016 |
Induction of Angiogenesis by a Type III Phosphodiesterase Inhibitor, Cilostazol, Through Activation of Peroxisome Proliferator-Activated Receptor-γ and cAMP Pathways in Vascular Cells.
Topics: Angiogenesis Inducing Agents; Angiopoietin-1; Animals; Capillaries; Cells, Cultured; Cilostazol; Cyc | 2016 |
Cellular and ionic mechanisms underlying the effects of cilostazol, milrinone, and isoproterenol to suppress arrhythmogenesis in an experimental model of early repolarization syndrome.
Topics: Action Potentials; Animals; Cardiac Electrophysiology; Cardiovascular Agents; Cilostazol; Death, Sud | 2016 |
Hemisphere Asymmetry of Response to Pharmacologic Treatment in an Alzheimer's Disease Mouse Model.
Topics: Alzheimer Disease; Animals; Brain; Cilostazol; Disease Models, Animal; Functional Laterality; Male; | 2016 |
Synergistic Effects of Cilostazol and Probucol on ER Stress-Induced Hepatic Steatosis via Heme Oxygenase-1-Dependent Activation of Mitochondrial Biogenesis.
Topics: Alanine Transaminase; Animals; Anticholesteremic Agents; Cells, Cultured; Cilostazol; Disease Models | 2016 |
Cilostazol reduces blood brain barrier dysfunction, white matter lesion formation and motor deficits following chronic cerebral hypoperfusion.
Topics: Animals; Blood-Brain Barrier; Cell Survival; Cerebral Small Vessel Diseases; Cilostazol; Disease Mod | 2016 |
Neuroprotective Effects of Simvastatin and Cilostazol in L-Methionine-Induced Vascular Dementia in Rats.
Topics: Animals; Brain; Cilostazol; Dementia, Vascular; Disease Models, Animal; Endothelium, Vascular; Male; | 2017 |
Neuroprotection of Cilostazol against ischemia/reperfusion-induced cognitive deficits through inhibiting JNK3/caspase-3 by enhancing Akt1.
Topics: Animals; Apoptosis; Brain Ischemia; Caspase 3; Cilostazol; Cognition Disorders; Disease Models, Anim | 2016 |
Cilostazol inhibits uremic toxin-induced vascular smooth muscle cell dysfunction: role of Axl signaling.
Topics: Animals; Axl Receptor Tyrosine Kinase; Cell Line; Cell Movement; Cell Survival; Cilostazol; Cresols; | 2017 |
Cilostazol protects against microvascular brain injury in a rat model of type 2 diabetes.
Topics: Animals; Brain Injuries; Cilostazol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dis | 2017 |
Long-term cilostazol administration ameliorates memory decline in senescence-accelerated mouse prone 8 (SAMP8) through a dual effect on cAMP and blood-brain barrier.
Topics: Aging; Amygdala; Animals; Blood-Brain Barrier; Capillary Permeability; Cilostazol; Conditioning, Cla | 2017 |
Combination of cilostazol and probucol protected podocytes from lipopolysaccharide-induced injury by both anti-inflammatory and anti-oxidative mechanisms.
Topics: Albuminuria; Animals; Anti-Inflammatory Agents; Antioxidants; Cells, Cultured; Chemokine CCL2; Cilos | 2017 |
Anti-inflammatory effects of the selective phosphodiesterase 3 inhibitor, cilostazol, and antioxidants, enzymatically-modified isoquercitrin and α-lipoic acid, reduce dextran sulphate sodium-induced colorectal mucosal injury in mice.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cilostazol; Colitis; Dextran Sulfate; Disease Model | 2017 |
Antidepressant Effects of Aripiprazole Augmentation for Cilostazol-Treated Mice Exposed to Chronic Mild Stress after Ischemic Stroke.
Topics: Animals; Antidepressive Agents; Aripiprazole; Atrophy; Behavior, Animal; Brain; Cell Differentiation | 2017 |
Antiplatelet agents sarpogrelate and cilostazol affect experimentally-induced ventricular arrhythmias and mortality.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cilostazol; Coronary Occlusion; Cyclic AMP; D | 2008 |
Cilostazol preserves CA1 hippocampus and enhances generation of immature neuroblasts in dentate gyrus after transient forebrain ischemia in rats.
Topics: Analysis of Variance; Animals; Brain Ischemia; Bromodeoxyuridine; Carotid Artery Diseases; Cell Surv | 2009 |
The effects of cilostazol on nerve conduction velocity and blood flow: acute and chronic cauda equina compression in a canine model.
Topics: Action Potentials; Acute Disease; Animals; Blood Flow Velocity; Cauda Equina; Chronic Disease; Cilos | 2008 |
Activation of tyrosine hydroxylase prevents pneumonia in a rat chronic cerebral hypoperfusion model.
Topics: Animals; Bacteria; Carotid Stenosis; Chronic Disease; Cilostazol; Corpus Striatum; Cyclic AMP Respon | 2009 |
Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice.
Topics: Animals; Cilostazol; Disease Models, Animal; Fibrosis; Inflammation; Male; Mice; Mice, Inbred BALB C | 2009 |
Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage.
Topics: Animals; Brain; Brain Ischemia; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Disease Models | 2009 |
Selective phosphodiesterase-3 inhibitor cilostazol ameliorates experimental autoimmune encephalomyelitis.
Topics: Animals; Cilostazol; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Glycoprote | 2009 |
Multifaceted effects of selective inhibitor of phosphodiesterase III, cilostazol, for cerebral vasospasm after subarachnoid hemorrhage in a dog model.
Topics: Administration, Oral; Animals; Basilar Artery; Cerebral Angiography; Cilostazol; Cyclic Nucleotide P | 2009 |
Protein kinase A-dependent suppression of reactive oxygen species in transient focal ischemia in adrenomedullin-deficient mice.
Topics: Adrenomedullin; Animals; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleo | 2009 |
Cilostazol, a specific PDE-3 inhibitor, ameliorates chronic ileitis via suppression of interaction of platelets with monocytes.
Topics: Animals; Anti-Inflammatory Agents; Blood Platelets; Cell Movement; Chronic Disease; Cilostazol; Cycl | 2009 |
The effects of intravenous cilostazol and nimodipine on cerebral vasospasm after subarachnoid hemorrhage in an experimental rabbit model.
Topics: Animals; Basilar Artery; Cilostazol; Disease Models, Animal; Drug Therapy, Combination; Injections, | 2009 |
Vasculoprotective effect of cilostazol in aldosterone-induced hypertensive rats.
Topics: Aldosterone; Animals; Aorta; Atherosclerosis; Blood Pressure; Chemokine CCL2; Cilostazol; Disease Mo | 2010 |
Cilostazol enhances neovascularization in the mouse hippocampus after transient forebrain ischemia.
Topics: Adult Stem Cells; Animals; CA1 Region, Hippocampal; Cell Death; Cell Proliferation; Cilostazol; Dise | 2010 |
Cilostazol effectively reduces the decrease of flow volume in a thrombotic anastomosis model in a rat: a novel application of ultrasonography for evaluation.
Topics: Anastomosis, Surgical; Animals; Cilostazol; Disease Models, Animal; Iliac Artery; Male; Microsurgery | 2010 |
Cilostazol attenuates cerebral vasospasm after experimental subarachnoid hemorrhage.
Topics: Animals; Cilostazol; Disease Models, Animal; Male; Neuroprotective Agents; Random Allocation; Rats; | 2010 |
Suppression of encephalitogenic T-cell responses by cilostazol is associated with upregulation of regulatory T cells.
Topics: Administration, Oral; Animals; Antigens; Cell Differentiation; Cell Proliferation; Cilostazol; Cytok | 2010 |
Cilostazol prevents amyloid β peptide(25-35)-induced memory impairment and oxidative stress in mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Aspirin; Avoidance Learning; Cilostazol; Cytokine | 2010 |
Cilostazol attenuates ischemic brain injury and enhances neurogenesis in the subventricular zone of adult mice after transient focal cerebral ischemia.
Topics: Animals; Brain Infarction; Bromodeoxyuridine; Cell Count; Cerebral Ventricles; Cilostazol; CREB-Bind | 2010 |
Comparison of intrathecal cilostazol and nimodipine treatments in subarachnoid hemorrhage: an experimental study in rabbits.
Topics: Analysis of Variance; Animals; Basilar Artery; Calcium Channel Blockers; Cilostazol; Disease Models, | 2011 |
Cilostazol enhances integrin-dependent homing of progenitor cells by activation of cAMP-dependent protein kinase in synergy with Epac1.
Topics: Animals; Brain Ischemia; Cells, Cultured; Chemotaxis; Cilostazol; Cyclic AMP-Dependent Protein Kinas | 2011 |
[Protective effect of intranasal cilostazol administration on chronic injury after cerebral ischemia in mice].
Topics: Administration, Intranasal; Animals; Brain; Brain Ischemia; Cilostazol; Disease Models, Animal; Infa | 2011 |
Cilostazol in patients with ischemic stroke.
Topics: Animals; Brain Ischemia; Cilostazol; Disease Models, Animal; Humans; Phosphodiesterase 3 Inhibitors; | 2011 |
Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels.
Topics: Adenosine; Animals; Cardiotonic Agents; Cilostazol; Decanoic Acids; Disease Models, Animal; Drug Eva | 2011 |
Beneficial effect of anti-platelet therapies on atherosclerotic lesion formation assessed by phase-contrast X-ray CT imaging.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Body Weight; Brachiocephalic Trunk; Cell Adhesio | 2012 |
Cilostazol stimulates revascularisation in response to ischaemia via an eNOS-dependent mechanism.
Topics: Angiogenesis Inducing Agents; Animals; Blotting, Western; Capillaries; Cilostazol; Disease Models, A | 2012 |
Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia.
Topics: Administration, Oral; Animals; Antigens, CD; Brain; Brain Edema; Brain Ischemia; Calcium-Binding Pro | 2012 |
Cilostazol suppression of arterial intimal hyperplasia is associated with decreased expression of sialyl Lewis X homing receptors on mononuclear cells and E-selectin in endothelial cells.
Topics: Angioplasty, Balloon; Animals; Anti-Inflammatory Agents; Carotid Arteries; Carotid Artery Injuries; | 2012 |
Ginkgo biloba extract (GbE) enhances the anti-atherogenic effect of cilostazol by inhibiting ROS generation.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cilostazol; Cytokines; Disease Models, Animal; Drug Syn | 2012 |
Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model.
Topics: Animals; Antitubercular Agents; Cilostazol; Disease Models, Animal; Mice; Phosphodiesterase Inhibito | 2012 |
The protective effect of cilostazol on isolated rabbit femoral arteries under conditions of ischemia and reperfusion: the role of the nitric oxide pathway.
Topics: Animals; Cilostazol; Disease Models, Animal; Femoral Artery; Hindlimb; Ischemia; Male; Nitric Oxide; | 2012 |
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism.
Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo | 2013 |
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism.
Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo | 2013 |
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism.
Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo | 2013 |
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism.
Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo | 2013 |
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism.
Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo | 2013 |
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism.
Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo | 2013 |
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism.
Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo | 2013 |
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism.
Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo | 2013 |
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism.
Topics: Animals; Cilostazol; Disease Models, Animal; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neo | 2013 |
Two-wavelength near-infrared fluorescence for the quantitation of drug antiplatelet effects in large animal model systems.
Topics: Analysis of Variance; Animals; Aspirin; Blood Platelets; Cilostazol; Disease Models, Animal; Female; | 2012 |
Efficacy of concurrent administration of cilostazol and methotrexate in rheumatoid arthritis: pharmacologic and clinical significance.
Topics: Animals; Antirheumatic Agents; Apoptosis; Arthritis, Rheumatoid; Base Sequence; Cell Proliferation; | 2012 |
Efficacy of concurrent administration of cilostazol and methotrexate in rheumatoid arthritis: pharmacologic and clinical significance.
Topics: Animals; Antirheumatic Agents; Apoptosis; Arthritis, Rheumatoid; Base Sequence; Cell Proliferation; | 2012 |
Efficacy of concurrent administration of cilostazol and methotrexate in rheumatoid arthritis: pharmacologic and clinical significance.
Topics: Animals; Antirheumatic Agents; Apoptosis; Arthritis, Rheumatoid; Base Sequence; Cell Proliferation; | 2012 |
Efficacy of concurrent administration of cilostazol and methotrexate in rheumatoid arthritis: pharmacologic and clinical significance.
Topics: Animals; Antirheumatic Agents; Apoptosis; Arthritis, Rheumatoid; Base Sequence; Cell Proliferation; | 2012 |
Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus.
Topics: Animals; Blood Glucose; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Melli | 2012 |
Suppression of PU.1-linked TLR4 expression by cilostazol with decrease of cytokine production in macrophages from patients with rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Cells, Cultured; Cilostazol; Cytokines; Diseas | 2013 |
Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes.
Topics: Animals; Blood Glucose; Blotting, Western; Cholesterol; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent | 2013 |
Effects of cilostazol in kidney and skeletal striated muscle of Wistar rats submitted to acute ischemia and reperfusion of hind limbs.
Topics: Animals; Apoptosis; Caspase 3; Cilostazol; Disease Models, Animal; Hindlimb; In Situ Nick-End Labeli | 2012 |
Dilation of porcine retinal arterioles to cilostazol: roles of eNOS phosphorylation via cAMP/protein kinase A and AMP-activated protein kinase and potassium channels.
Topics: AMP-Activated Protein Kinases; Animals; Arterioles; Cilostazol; Cyclic AMP; Disease Models, Animal; | 2013 |
The impact of triple anti-platelet therapy for endothelialization and inflammatory response at overlapping bioabsorbable polymer coated drug-eluting stents in a porcine coronary model.
Topics: Absorbable Implants; Animals; Aspirin; Cilostazol; Clopidogrel; Coated Materials, Biocompatible; Cor | 2013 |
Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol.
Topics: Alprostadil; Animals; Body Weight; Cilostazol; Disease Models, Animal; Exercise Test; Intermittent C | 2003 |
Antiplatelet and antithrombotic activity of cilostazol is potentiated by dipyridamole in rabbits and dissociated from bleeding time prolongation.
Topics: Animals; Bleeding Time; Carotid Artery Thrombosis; Cilostazol; Dipyridamole; Disease Models, Animal; | 2005 |
Cilostazol attenuates gray and white matter damage in a rodent model of focal cerebral ischemia.
Topics: Animals; Axons; Brain; Brain Ischemia; Cerebrovascular Circulation; Cilostazol; Disease Models, Anim | 2006 |
Effect of cilostazol, a selective type-III phosphodiesterase inhibitor, on water-immersion stress-induced gastric mucosal injury in rats.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Chemokine CXCL1; Chemokines, CXC; Cilostazol; Cyclic N | 2006 |
Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion.
Topics: Administration, Oral; Animals; Apoptosis; Brain; Brain Ischemia; Caspase 3; Caspases; Cilostazol; Di | 2006 |
Differential effects of phosphodiesterase PDE-3/PDE-4-specific inhibitors on vasoconstriction and cAMP-dependent vasorelaxation following balloon angioplasty.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Angioplasty, Balloon; Animals; Aorta; Carboxylic Acids; Cilosta | 2007 |
Attenuation of gastric mucosal inflammation induced by aspirin through inhibition of selective type III phospshodiesterase in rats.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Anti-Inflammatory Agents; Aspirin; Chemokine CXCL1; Ch | 2007 |
Cilostazol protects rat chondrocytes against nitric oxide-induced apoptosis in vitro and prevents cartilage destruction in a rat model of osteoarthritis.
Topics: Animals; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Cartilage, Articular; Casein Kinas | 2008 |
Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction.
Topics: Animals; Arrhythmias, Cardiac; Cilostazol; Disease Models, Animal; Echocardiography; Electrocardiogr | 2008 |
Cilostazol therapy attenuates monocrotaline-induced pulmonary arterial hypertension in rat model.
Topics: Animals; Blood Pressure; Body Weight; Cilostazol; Connexin 43; Disease Models, Animal; Endothelium, | 2008 |
Nerve function and blood flow in Otsuka Long-Evans Tokushima Fatty rats with sucrose feeding: effect of an anticoagulant.
Topics: 2,3-Diphosphoglycerate; Alcohols; Animals; Anticoagulants; Blood Glucose; Body Weight; Carbohydrate | 1996 |
Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Carotid Arteries; Cilostazol; Cyclic Nucleotide Phosph | 1999 |
The effect of cilostazol on glucose tolerance and insulin resistance in a rat model of non-insulin dependent diabetes mellitus.
Topics: Animals; Animals, Newborn; Blood Glucose; Cilostazol; Diabetes Mellitus, Type 2; Disease Models, Ani | 2001 |
Effect of cilostazol, a new antithrombotic drug, on an experimental model of peripheral circulation insufficiency.
Topics: Animals; Arterial Occlusive Diseases; Aspartate Aminotransferases; Azoles; Cilostazol; Creatine Kina | 1985 |